Sulfonamides

SULFONAMIDES This invention relates to sulfonamides and in particular to sulfonamides wherein the sulfonamide group is located adjacent to a hydroxamate group. This invention further relates to processes for preparing such sulfonamides, to pharmaceutical compositions containing them and to their use in methods of therapeutic treatment.

The compounds of this invention are inhibitors of the production of TNF (TumourNecrosis Factor) which is believed to be formed by the cleavage of a pro-form. or larger precursor. by the enzyme pro-TNF Convertase Applicants believe that the compounds of the present invention inhibit TNF production by mechanisms which include inhibition of proTNF Convertase. The term 'TNF' is used herein to refer to Tumour Necrosis Factor in general but, in particular, to TNFct.

The compounds of this invention will be useful in the treatment of disease or medical conditions in which excessive TNF production is known to give rise via a cascade of processes to a variety of physiological sequelae including the production of physiologicallyactive eicosanoids such as the prostaglandins and leukotrienes. the stimulation of the release of proteolytic enzymes such as collagenase, the activation of osteoclast activity leading to the resorption of calcium, the stimulation of the release of proteoglycans from, for example, cartilage, the stimulation of cell proliferations and to angiogenesis. it is also known that, in certain cellular systems.STDC0869 TNF production precedes and mediates the production of other cytokines such as interleukin-l (IL-I) and interleukin-2 (IL-2) which are also believed to contribute to the pathology of disease states such as inflammatory and allergic diseases and cytokine-induced toxicity. Excessive TNF production has also been implicated in mediating or exacerbating the development of various inflammatory and allergic diseases such as inflammation of the joints (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastrointestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), skin disease (especially psoriasis, eczema and dermatitis) and respiratory disease (especially asthma, bronchitis and allergic rhinitis), and in the production and development of various cardiovascular disorders such as myocardial infarction,STDC0683 angina and peripheral vascular disease. Excessive TNF production has also been implicated in mediating complications of bacterial, fungal and/or viral infections such as endotoxic shock, septic shock and toxic shock syndrome. Excessive TNF production has also been implicated in mediating or exacerbating the development of adult respiratory distress syndrome, diseases involving cartilage or muscle resorption, Paget's disease and ostcoporosis, pulmonary fibrosis, cirrhosis, renal fibrosis, the cachexia found in certain chronic diseases such as malignant disease and acquired immune deficiency syndrome (AIDS), tumour invasiveness and tumour metastasis and multiple sclerosis.

The compounds of the invention may also be inhibitors of one or more matrix metalloproteinases such as collagenases, stromelysins and gelatinases. Thus they may also be of use in the therapeutic treatment of disease conditions mediated by such enzymes for example arthritis (rheumatoid and osteoarthritis). osteoporosls and tumour metastatis.

The present invention provides novel sulfonamides which have activity as inhibitors of TNF and/or are inhibitors of one or more matrix metalloproteinase enzymes.

Accordingly the present invention provides a compound of the formula (I):EMI2.1 wherein:R1 is is aryl, heterocyclyl or heteroaryl; R2 is is hydrogen, C1-8alkyl, C2 6alkenyl, C2.6alkynyl, C3-8cycloalkyl, aryl, heteroaryl, heterocyclyl, arylC1-6alkyl, heteroarylC 1.6alkyl, heterocyclylC, 6alkyl or C3-8cycloalkylC1-6alkyl;R3 is C1.6alkyl, C2.6alkenyl, arylC1-6alkyl, heteroarylC, 6alkyl or the side-chain of a naturally occurring amino acid;R4 is hydrogen, C1-6alkyl, C3-8cycloalkyl, C4-8cycloalkenyl, arylC1-6alkyl, heteroarylC, 6alkyl or heterocyclylC, .6alkyl; R5 is hydrogen or C1-6alkyl;STDC0264 or R4 or R5 together with the nitrogen atom to which they are joined form a heterocyclic ring; wherein any group or ring, in R'-R4. is optionally substituted; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.

"Aryl in the terms "aryl" and "arylC1-6alkyl" typically means phenyl or naphthyl, preferably phenyl. "Heteroaryl" in the terms "heteroaryl" and 'heteroarylC1.6alkyl" means an aromatic mono- or bicyclic 5-10 membered ring with up to five ring heteroatoms selected from nitrogen, oxygen and sulphur. Examples of heteroaryl include thienyl, pyrrolyl furanyl, imidazolyl thiazolyl, pyrimidinyl, pyridinyl, indolyl, benzimidazolyl benzthiazolyl quinolinyl and isoquinolinyl. "Heterocyclyl" in the terms "heterocyclyl" and "hcterocyclylC1-6alkyl" means a non-aromatic mono- or bicyclic 5-10 membered nng with up to five ring hetero atoms selected from nitrogen, oxygen and sulphur.STDC0117 Examples of heterocyclyl' include pyrrolidinyl. morpholinyl, piperidinyl, dihydropyridinyl and dihydropyrimidinyl.

Any group or ring in R'-R5 may be optionally substituted, for example by up to five substituents, preferably up to three substituents which may be the same or different. Typical substituents include: hydroxy, C, 6alkoxy for example methoxy, mercapto, C,.6alkylthio for example methylthio, amino C,.6alkylamino for example methylamino di-(C, 6alkyl)amino for example dimethylamino, carboxy, carbamoyl, C, 6alkylcarbamoyl for example methylcarbamoyl, di-C6alkylcarbamoyl for example dimethylcarbamoyl. C1-6alkylsulphonyl for example methylsulphonyl, arylsulphonyl for example phenylsulphonyl, Cl 6alkylaminosulphonyl for example methylaminosulphonyl.STDC0875 di-(C1-6alkyl)aminosulphonyl for example dimethylaminosulphonyl, nitro, cyano, cyano-C1-6alkyl for example cyanomethyl, hydroxyC1-6alkyl for example hydroxymethyl, amino-C, 6alkyl for example aminoethyl, Cl4alkanoylamino for example acetamido, C, C1-6alkoxycarbonylamino for example methoxycarbonylamino, C, 6alkanoyl for example acetyl, C, 6alkanoyloxy for example acetoxy, C1.6alkyl for example methyl, ethyl, isopropyl or tert-butyl, halo for example fluoro, chloro or bromo, trifluoromethyl, aryl for example phenyl, arylC, 6alkyl for example benzyl, aryloxy for example phenoxy, arylC1-6alkoxy for example benzyloxy, heteroaryl, heteroarylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl A further typical substituent is trifluoromethoxy.STDC0462 The term "side chain of a naturally occurring amino acid" means the side chain X of an amino acid NH2-CHX-COOH. Suitable amino acids include alanine, arginine, aspartic acid, cysteine. asparagine, glutamine, histidine. homoserine, isoleucine. leucine, lysine, methionine, norleucine, norvaline, ornithine, serine, threonine, tryptophan, tyrosine and valine.

The compounds of the present invention possess a number of chiral centres, at -CHtNHSOR')-, at -CHR3-, at -CHR2- (when R2 is not hydrogen) and possibly in the variables R'-R5. The present invention covers all diastereoisomers and mixtures thereof that inhibit TNI: Convertase and/or inhibit matrix metalloproteinase enzymes.

Suitably R' is an optionally substituted phenyl group or optionally substituted naphthyl group. Favourably R' is phenyl or naphthyl wherein either ring is unsubstituted or substituted by one or two groups selected from halogen for example chloro or fluoro,C1-6alkylcarbonyl for example acetyl. C1-6alkanoylamino for example acetasmido, trifluoromethyl, cyano, C1-6alkyl for example methyl, Isopropyl or tert-butyl, trifluoromethoxy, carboxy, nitro. di-CI 6alkylamino for example dimethylamino or is C, 6alkoxy for example methoxy.

In one aspect R' is phenyl or naphthyl wherein either ring is unsubstituted or substituted by one or two groups selected from halogen for example chloro or fluoro,C, 6alkylcarbonyl for example acetyl, C1.6alkanoylamino for example acetamido, trifluoromethyl, cyano, C1-6alkyl for example methyl, isopropyl or tert-butyl, or is C, 6alkoxy for example methoxy.

Preferably R' is phenyl, 4-fluorophenyl 4-trifluoromethylphenyl, 2-cyanophenyl, 3,5-difluorophenyl, 4-acetylphenyl, 4-acetamidophenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl or 3,5-dichlorophenyl. Preferably also R1 is 2,4,6-trimethylphenyl, 3 -trifluoromethyl, 4-carboxyphenyl, 4-bromophenyl, 3-chiorophenyl 2-chloro-4fluorophenyl, 4-isopropylphenyl, 3 -nitropheny I, 3-carboxyphenyl or 2,4,6-triisopropylphenyl. Most preferably Ri is phenyl or 4-acetylphenyl.

Preferably also R' may be naphth-l-yl or naphth-2-yl or naphthyl optionally substituted such as 5-dimethylaminonaphth- 1 -yl or 5-dimethylaminonaphth-2-yl.

In another aspect suitably R' is an optionally substituted heteroaryl group as hereinbefore defined. More particularly R' is an optionally substituted heteroaryl group wherein the heteroaryl group has 5 or 6 ring atoms, one to three of which are selected from nitrogen and sulphur or is a bicyclic derivative thereof wherein two adjacent carbon atoms are fused to a benzene ring.

Examples ofRi being a monocyclic heteroaromatic ring include pyridazinyl, pyrimidinyl, pyridinyl. triazolyl, imidazolyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl and isoxazolyl. any of which may be optionally substituted for example by C1-6alkyl such as methyl. halo such as chloro, fluoro or bromo, phenyl or pyridinyl. In one aspect RI is pyridazinyl, pyrimidinyl, pyridinyl, triazolyl, imidazolyl. thienyl, pyrrolyl or thiazolyl.

Preferably RI is a bicyclic heteroaromatic ring system wherein one or both rings may contain ring heteroatoms and wherein the sulfonamide link may be to either ring.

Favourably one ring is a benzene ring fused on two adjacent carbon atoms to a 5- or 6membered nitrogen containing ring which ring may be saturated or unsaturated. Examples of' such favoured ring systems include quinolinyl. isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, quinazolinyl. 3 .4-dihydroquinazolinyl, indolyl. benzofuranyl. benzthiazolyl. benzofurazanyl and isoindolyl. Suitably such ring systems may be optionally substituted as described hereinbefore, in particular by C16alkyl for example methyl and by oxo (= O).STDC0325 Particular ring systems include quinolin-8-yl, quinolin-6-yl. l-methyl-2-oxo-1 ,2 3 .4-tetrahydroquinolin-6-yl, oxindol-5-yl, isoquinolin-5-yl, 1,2,3 ,4-tetrahydroquinolin-8-yl 4-oxo-34-dihydroquinazolin- 8-yl and 4-oxo-3,4-dihydroquinazolin-6-yl.

In a further aspect R' may be an optionally substituted heterocyclyl group as hereinbefore defined. More particularly R' is an optionally substituted heterocyclyl group having 5 or 6 ring atoms, one to three of which are selected from nitrogen, oxygen or sulphur.

Examples of particular heterocyclyl groups include tetrahydropyran, tetrahydrofuran, piperidine and bicyclic derivatives thereof wherein two adjacent carbon atoms are fused to another ring.

There is a chiral centre at -CH(NHSO2R'); it is preferred that this centre has the configuration indicated in formula (II) hereinafter. For most values of R' this centre will have the S-stereochemistry under the Cahn-Prelog-lngold sequence rules.

Particular groups for R2 include C, xalkyl for example isopropyl, n-propyl, isobutyl, sec-butyl, n-butyl, tert-butyl, isopentyl, n-pentyl, hexyl, heptyl or octyl; C1-8alkyl interrupted by an oxygen or sulphur atom for example methoxypropyl, ethoxyethyl, propoxymethyl, ethylthioethyl, methylthiopropyl; phenylC, 6alkyl for example benzyl, phenethyl, phenylpropyl or phenylbutyl; phenylC1-6alkyl wherein the alkyl chain is interrupted by oxygen or sulphur for example benzyloxypropyl and benzyloxybutyl; C3 8cycloalkyl for example cyclopropyl cyclobutyl. cyclopentyl or cyclohexyl: or C3-8cycloalkylC1-6alkyl for example cyclopropylmethyl cyclopropylethyl. cyclobutylmethyl, cyclopentylmethyl or cyclohexylmethyl.

In a particular aspect R2 may be C,.8alkyl for example isopropyl, n-propyl, isobutyl, sec-butyl, n-butyl, tert-butyl, isopentyl n-pentyl. hexyl, heptyl or octyl; C1-8alkyl interrupted by an oxygen or sulphur atom for example methoxypropyl, ethoxyethyl. propoxymethyl.

ethylthioethyl or methylthiopropyl; phenylC1 .6alkyl for example benzyl, phenethyl.

phenylpropyl or phenylbutyl; C3 8cycloalkyl for example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; or C3-8cycloalkylC1-6alkyl lbr example cyclopropylmethyl, cyclopropylethyl.

cyclobutylmethyl. cyclopentylmethyl or cyclohexylmethyl.

Preferably R2 is isobutyl.

There is a chiral centre at -CHR2- (when R2 is not hydrogen); it is preferred that this centre has the configuration indicated in formula (II) hereinafter. For most values of R2 this centre will have the R-stereochemistry under the Cahn-Prelog-Ingold sequence rules.

Particular groups for R3 include C1-6alkyl for example methyl, ethyl, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl isopentyl, n-pentyl or hexyl; C1-6alkyl interrupted by an oxygen or sulphur atom for example methoxyethyl, methoxypropyl, methylthioethyl or 1,1-dimethylmethylthiomethyl (MeSCMe2-); or phenylC1 ,6alkyl for example benzyl or phenethyl.

Preferably R3 is isobutyl, tert-butyl, 1,1-dimethylmethylthiomethyl or benzyl with tert-butyl being most preferred.

The chiral centre at -CHR3- preferably has the configuration indicated in formula (II) hereinafter. For most of R3 this centre will have the S-stereochemistry.

Particular groups for R4 include C1-6alkyl for example methyl, ethyl, n-propyl, isopropyl, tert-butyl or n-butyl; C1-6alkyl interrupted by an oxygen or sulphur atom for example hydroxyethyl, methoxyethyl, methylthioethyl or ethoxyethyl; phenylC, 6alkyl for example benzyl, phenethyl or phenylpropyl; or C3 ScycloalkylCl 6alkyl for example cyclopropylmethyl, cyclobutylmethyl or cyclopentylmethyl.

Particularly also, R4 may be C1-6alkylaminoC2-6alkyl for example methylaminoethyl, di-C1 6alkylaminoC2-6alkyl for example dimethylaminoethyl or dimethylaminopropyl, or is heterocyclieC 6alkyl for example 2-morpholinoethyl, 2-piperidinoethyl 2-piperazinoethyl or 2-(N-methyl)piperazinoethyl.

Preferably R4 is methyl. ethyl. n-propyl isobutyl, tert-butyl, dimethylaminoethyl, dimethylaminopropyl, morpholinoethyl or benzyl. Of these methyl is most preferred.

Particular groups for R5 are hydrogen and C1,alkyl for example methyl or ethyl.

Preferably R5 is hydrogen.

In another aspect R4 and Rs together with the nitrogen atom to which they are joined form a heterocyclic ring, for example a 5 or 6 membered heterocyclic ring such as morpholino, piperidino, piperazino or N-methylpiperazino. Of these morpholino is preferred.

A particularly suitable class of compounds of the present invention is that of formula (II): EMI7.1 wherein Rl, R2, R3, R4 and R5 are as hereinbefore defined.

A preferred class of compounds of the formula (II) is that wherein RI is phenyl or naphthyl either being unsubstituted or substituted by one or two groups selected from halogen for example chloro or fluoro, C1-6alkylcarbonyl for example acetyl, C1-6alkanoylamino for example acetamido, trifluoromethyl, cyano, C1-6alkyl for example methyl, isopropyl or tertbutyl, trifluoromethoxy, carboxy, nitro, di-C1-6alkylamino for example dimethylamino or is C l 6alkoxy for example methoxy;STDC0868 or R1 is pyridazinyl, pyrimidinyl, pyridinyl, triazolyl, imidazolyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl or oxazolyl any of which is unsubstituted or substituted by C1 6alkyl for example methyl, halo for example chloro. fluoro or bromo, phenyl or pyridinyl; or R1 is quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, quinazolinyl, 3,4dihydroquinazolinyl, indolyl, benzofuranyl, benzothiazolyl, benzofurazanyl or isoindolyl any of which is unsubstituted or substituted by C1-6alkyl for example methyl and/or oxo(= 0); R2 is isobutyl:R3 is isobutyl, tert-butyl, lsl-dimethylmethylthiomethyl or benzyl;R4 is methyl, ethyl, n-propyl, isobutyl tert-butyl, dimethylaminoethyl. dimethylaminopropyl, 2-morpholinoethyl or benzyl; and Rs is hydrogen or methyl:STDC0823 or K4 and Rs together with the nitrogen atom to which they are joined form a morpholine ring In one aspect a preferred class of compounds of the formula (II) is that wherein Rl Is phenyl or naphthyl unsubstituted or substituted by one or two groups selected from halogen for example chloro or fluoro, C, 6alkylcarbonyl for example acetyl, C, "alkanoylamino for example acetamido, trifluoromethyl, cyano. C1.6alkyl for example methyl, isopropyl or tertbutyl or C1.6alkoxy for example methoxy; R3 is isobutyl, 1,1 -dimethylmethylthiomethyl, tertbutyl or benzyl; R4 is methyl, ethyl, n-propyl, isobutyl, tert-butyl or bcnzyl; and R5 is hydrogen.

A particular class of preferred compounds Is that wherein RI is quinolin-8-yl, quinolin-6-yl, 1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl, oxindol-5-yl, isoquinolin-5-yl, 1,2,3 ,4-tetrahydroquinolin-8-yl, 4-oxo-3 ,4-dihydroquinazolin-8-yl or 4-oxo-3,4- dihydroquinazolin-6-yl;R2 is isobutyl;R3 is isobutyl, tert-butyl, l,1-dimethylmethylthiomethyl or benzyl;R4 is methyl, ethyl, n-propyl, isobutyl, tert-butyl, dimethylaminoethyl, dimethylaminopropyl, 2-morpholinoethyl or benzyl; and Rs is hydrogen or methyl; or R4 and Rs together with the nitrogen atom to which they are joined form a morpholine ring.

Suitable pharmaceutically acceptable salts include acid addition salts such as hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, or organic amine salt for example triethylamine.

In vivo hydrolysable esters are those pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent compound. Such esters can be identified by administering, for example intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable in vivo hydrolysable esters for carboxy include methoxymethyl and for hydroxy include acetyl.

In order to use a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans. it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester and pharmaceutically acceptable carrier.

?'he pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it Is desired to treat. for example by oral, topical, parenteral buccal, nasal, vaginal or rectal administration or by inhalation. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.

In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to hereinabove.

The pharmaceutical compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.5 to 75 mg/kg body weight (and preferably of 0.5 to 30 mg/kg body weight) is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease condition being treated according to principles known in the art.

Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.

Therefore in a further aspect, the present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for use in a method of therapeutic treatment of the human or animal body.

In yet a further aspect the present invention provides a method of treating a disease condition mediated by TNF which comprises administering to a warm-blooded animal an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. ?'he present invention also provides the use of a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof in the preparation of a medicament for use in a disease condition mediated by TNF.

In another aspect the present invention provides a process for preparing a compound of the formula or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process comprises a) reacting a compound of the formula (III): EMI10.1 wherein R'-R5 are as hereinbefore defined, or an activated derivative thereof with hydroxylamine, O-protected hydroxylamine or a salt thereof; or b) coupling a compound of the formula (IV) with a compound of the formula (V): EMI11.1 wherein R'-Rs are as hereinbefore defined, under standard peptide coupling conditions;STDC0508 or c) reacting a compound of the formula (VI) with compound of the formula (VII):EMI11.2 NHR4R5 (VII) or d) reacting a compound of the formula (VIII) with a compound of the formula (IX): EMI12.1 R1S02X (IX) wherein R'-R5 are as hereinbefore defined and X is a leaving group: wherein any functional group is protected, if necessary. and: i. removing any protecting groups; ii. optionally forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.

Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question. and may be introduced by conventional methods.

Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

Specific examples of protecting groups are given below for the sake of convenience, in which "lower" signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.

A carboxyl protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).

Examples of carboxy protecting groups include straight or branched chain (l-12C)alkyl groups (eg isopropyl, L-butyl); lower alkoxy lower alkyl groups (eg methoxymethyl, ethoxymethyl, isobutoxymethyl): lower aliphatic acyloxy lower alkyl groups, (eg acetoxymethyl, propionyloxvmethyl, butyryloxymethyl, pivaloyloxymethyl): lower alkoxycarbonyloxy lower alkyl groups (eg 1-methoxycarbonyloxyethyl 1 -ethoxycarbonyloxyethy 1); aryl lower alkyl groups (eg benzyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (cg trimethylsilyl and t-butyldimethylsilyl); tri(lower alkyl)silyl lower alkyl groups (eg trimethylsilylethyl); and (2-6C)alkenyl groups (eg allyl and vinylethyl).

Methods particularly appropriate for the removal of carboxyl protecting groups include for example acid-, base-. metal- or enzymically-catalysed hydrolysis.

Examples of hydroxyl protecting groups include lower alkyl groups (eg t-butyl). lower alkenyl groups (eg allyl); lower alkanoyl groups (eg acetyl); lower alkoxycarbonyl groups (eg t-butoxycarbonyl): lower alkenyloxycarbonyl groups (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzoyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl); tri(lower alkyl)silyl (eg trimethylsilyl, t-butyldimethylsilyl) and aryl lower alkyl (eg benzyl) groups.

Examples of amino protecting groups include formed aralkyl groups (eg benzyl and substituted benzyl, p-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-p-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (eg t-butoxycarbonyl); lower alkenyloxycarbonyl (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, E-nitrobenzyloxycarbonyl); trialkylsilyl (eg trimethylsilyl and t-butyldimethylsilyl); alkylidene (eg methylidene); benzylidene and substituted benzylidene groups.STDC0333 Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or enzymically-catalysed hydrolysis, for groups such as Ey- nitrobenzyloxycarbonyl, hydrogenation and for groups such as q-nitrobenzyloxycarbonyl, photolytically.

Compounds of the formula (I) may be converted to other compounds of the formula (I) by standard chemical methodologies. for example hydrogenation of a quinoline to a 1 ,2,3,4-tetrahydroquinoline.

The hydroxylamine group (HONlI-), in particular in process variants (b), (c) and (d).

is typically O-protected for example with benzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, t-butyl or a silyl (for example trimethylsilyl) group.

In process variant a), the compound of the formula (III) may be reacted in the form of the acid or an activated derivative thereof such as an acid halide, acid anhydride or an 'activated' cster such as 1H-benzo[1,2,3]triazol-1-yl, 1-hydroxy-benzo[1,2,3]triazole, pentafluorophenyl or 2,4,5-trichlorophenyl in the presence of a carbodiimide. The reaction of the compound of the formula (III) and hydroxylamine Is performed under standard conditions.

Typically the reaction of an activated ester of a compound of the formula (III ) and hydroxylamine or O-protccted hydroxylamine is performed in the presence of a base, for example 2,6-lutidine (optionally in the presence of dimethylaminopyridine) orN-methylmorpholine in an anhydrous aprotic solvent, for example dimethylformamide. at a non-extreme temperature, for example In the region -30" to +250, preferably about 0 C.

The compound of the formula (III) may be prepared by reacting a compound of the formula (IX) with a compound of the formula (X):EMI14.1 wherein R2-R5 are as hereinbefore defined and wherein the carboxylic acid function is typically protected. for example by a tert-butyl group, which protection is removed subsequent to the reaction. The conditions for reacting the compounds of the formula (IX) and (X) are similar to those described hereinafter for the reaction of compounds of the formulae (VIII) and (IX).

The compounds of the formula (X), optionally with the carboxylic acid function protected, may be prepared by coupling a suitably protected compound of the formula (XI): EMI15.1 wherein R2 is as hereinbeforc defined.. with a compound of the formula (V). The compounds of the formula (XI) may be prepared in standard manner, for example by the alkylation of protected aspartic acid derivatives or by the reaction of a glycine nucleophilic equivalent with a compound of the formula: R?-CI IX I-COOH (protected as necessary) wherein X i is a leaving group for example a triflate.

In an alternative the compounds of the formula (X) optionally with the carboxylic acid function protected, may be prepared by coupling a suitably protected compound of the formula (XII): EMI15.2 wherein R2 and R3 are as hereinbefore defined with a compound of the formula (VII). The compounds of the formula (XII) may be prepared by coupling suitably protected compounds of the formulae (XI) and (XIII):EMI15.3 wherein R3 is as hereinbefore defined.

In process variant b), the compounds of the formulae (IV) and (V) are reacted under standard peptide coupling conditions wherein any functional group is protected as necessary.

The compounds of the formula (IV) may be prepared by reacting a suitably protected compound of the formula (XIV): EMI16.1 wherein Rl and R2 are as hereinbefore defined with hydroxylamine in a manner similar to that described hereinabove for converting a compound of the formula (III) to a compound of the formula (I). The compounds of the formula (XIV) may be prepared by reacting a compound of the formula (X1) with a compound of the formula (IX).

In an alternative the compounds of the formula (IV) may be prepared by reacting a suitably protected compound of the formula (XV):EMI16.2 wherein R2 is as hereinbefore defined. with a compound of the formula (IX). The compounds the formula (XV) may be prepared by reacting a compound of the formula (Xl) with hydroxylamine in a manner similar to that described hereinabove.

The compounds of the formula (V) may be prepared by reacting a compound of the formula (XIII) with a compound of the formula (VII) under standard coupling conditions.

In process variant c), the compounds of the formulae (VI) and (VII) arc reacted under standard conditions for acylation of an amine with any functional groups protected as necessary.

'Ihe compounds of the formula (VI) may be prepared by reacting a compound of the formula (XVI):EMI17.1 wherein R1-R3 are as hereinbefore defined with hydroxylamine in a manner similar to that described above. The compounds of the formula (XVl) may be prepared by reacting compounds of the formulae (IX) and (XII) or by reacting compounds of the formulae (Xlll) and (XIV) under conditions similar to those described above for similar reactions.

The compounds of the formula (VI) may also be prepared by reacting compounds of the formula (IV) and (XIII) or by reacting compounds of the formulae (IX) and (XVII):EMI17.2 wherein R2 and R3 are as hereinbefore defined. The compounds of the formula (XVII) may be prepared by reacting compounds of the formula (XII) with hydroxylamine.

In process variant d), the compounds of the formula (VIII) and (IX) are reacted under standard conditions for sulphonylation of an amine with any functional groups protected as necessary. In the compounds of the formula (IX) X is a leaving group.

Preferably X is halo for example fluoro, chloro or bromo, or X is an anhydride-forming group or an ester-forming group. Most favourably X is chloro or bromo. The compounds of the formula (VIII) may be prepared by reacting compounds of the formulae (V) and (XV), or by reacting compounds of the formulae (XVII) and (VII). or by reacting a compound of the formula (X) with hydroxylamine.

The following biological test methods, data and Examples serve to illustrate the present invention.

Isolated Enzyme Assay The ability of the compounds of this invention to inhibit proTNl;cx convertase enzyme is assessed in an isolated enzyme assay (termed "CON2"). Partially purified proTNFa convertase enzyme is obtained from the membranes of THP-1 cells as follows.

1.5-2.0X10 cells/ml THP-I cells (initially cultured in KPM11640 medium + l0%(v/v) FCS, 10%(v/v)M1. 2mM L-glutamine 100IU/ml penicillin and 1 00ptg/ml streptomycin) are induced in RPMI 1640 containing IHg/ml LPS (E. coli 011 l:B4), 2mM llydroxyurea, 50 g/ml silica and 1%(v/v) FCS at 370C in a humidified (5%CO2/95%air) incubator. After 16 hours the cells are harvested from a 5L induction by centrifugation at 640xg for 15 minutes. The cell pellets are washed once in RPMI 1640 without additive (1L per 2x1010 cells) and re-centrifuged at 640xg for 10 minutes.STDC0735 Cell pellets are resuspended in lOmM sodium phosphate buffer pH 7.4, containing ImM MgCI2 30mM NaCI, 5 M PMSF, 0.02%(w/v) sodium azide (Buffcr A) plus a few micrograms DNAase using 3 times the volume of buffer to packed cell pellets. A polytron homogeniser is used to lyse the cells by 5x5sec bursts with 1-2 minutes cooling between each bursl. 30 ml of this homogenate is layered onto 10 mls of 41% (w/v) sucrose made in Buffer A and centrifuged at 150,000xg for 1 hour in a swing out rotor. The membrane is collected from the interphase, diluted by addition of 4 volumes Buffer A and centrifuged at 150,000xg for 20 minutes.STDC0633 The pellet is then resuspended in Buffer A containing 1 %(w/v) Triton X- 100 to a concentration of 1 mg/ml and mixed for 1 hour at 40C. The solubilised protein is recovered by centrifugation for 30 minutes at 1 00,000xg at 40C. The supernatant is applied to a 25ml gelatin-sepharose 4B column equilibrated in 10mM Tris-HCl pH 8.0, 1 OOmM NaCI, 0.1%(w/v) Triton X-100, 200 M PMSF, 0.02%(w/v) azide, 1 pM ZnCI2 (Buffer B). After loading the column is washed with Buffer B.STDC0666 The gelatin-sepharose flowthrough plus the first 10mls of the wash is then recycled overnight (lml/min) on a 30ml wheatgerm-sepharose column previously equilibrated in l0mM Tris-HCl pli 8.0, 0.1%(w/v) Triton X-100, 200 M PMSF, 0.02%(w/v) azide, 1 pM ZnCl2 (Buffer C). After loading the column is washed in Buffer C and the enzyme is eluted with Buffer C containing 300mM N-Acetyl Glucosamine. The active enzyme fractions are applied to a lml Mono Q column equilibrated in Buffer C. After loading and washing with Buffer C, enzyme is eluted using a 0-500mM NaCI gradient in Buffer C.

Active enzyme fractions are pooled and used as partially purified proTNFa convertase. In all cases the active fractions are assayed using the fluorogenic synthetic peptide substrate assay described below. This enzyme preparation cleaves 21kD soluble proTNFot at the correct cieavage site (Ala-Val) and enzyme activity is inhibited by matrix metalloprotease inhibitors (Gearing, A.J.H. et al., 1995, J Leukocyte Blol., 57,774-777). 4'.5'-Dimethoxy-fluoresceinyl Ser.Pro.Leu.Ala.Gln.Ala.Val.Arg.Ser.Ser.Ser.Arg.Cys(4-(3-succinimid- 1 -yl)-fluorescein)- NH the substrate is used to measure proTNFo convertase enzyme activity in CON2. It was synthesised as follows.STDC0833 The peptidic part of the substrate was assembled on Fmoc-Nid-Rink- MBHA-polystyrene resin either manually or on an automated peptide synthesiser by standard methods involving the use of Fmoc-amino acids and O-benzotriazol-1-yl-N,N,N',N'- tetramethyluronium hexafluorophosphate (HBTU) as coupling agent with at least a 4- or 5fold excess of Fmoc-amino acid and HBTU. Ser' and Pro2 were double-coupled. The following side chain protection strategy was employed; Ser'(Bu'), Gln5(Trityl), Arg8'12(Pmc or Pbf), Ser9'10'1 '(Trityl), Cys'3(Trityl). Following assembly, the N-terminal Fmoc protecting group was removed by treating the Fmoc-peptidyl-resin with piperidine in DMF.STDC0860 The aminopeptidyl-resin so obtained was acylated by treatment for 1.5-2hr at 700C with 1.5-2 equivalents of 4',5'-dimethoxy-fluorescein-4(5)-carboxylic acid (Khanna & Ullman, AnalBiochem, 108, 156- 161, 1980) which had been preactivated with diisopropylcarbodiimide and 1 -hydroxybenzotriazole in DMF. The dimethoxyfluoresceinyl-peptide was then simultaneously deprotected and cleaved from the resin by treatment with trifluoroacetic acid containing 5% each of water and triethylsilane. The dimethoxyfluoresceinyl-peptide was isolated by evaporation, trituration with diethyl ether and filtration. The isolated peptide was reacted with 4-(N-maleimido)-fluorescein in DMF containing diisopropylethylamine, the product purified by RP-HPLC and finally isolated by freeze-drying from aqueous acetic acid.

The product was characterised by MALDI-TOF MS and amino acid analysis.

Test compounds are serially diluted in assay buffer (50mM Tris HCI, pH 7.4 containing 0.1% (w/v) Triton X- 100 and 2mM CaCI2) and 50p1 of each concentration is added to appropriate wells of a 96 well plate and 50p1 assay buffer is added to substrate alone (n=6) and substrate *enzyme (n=6) control wells. ProTNFα convertase enzyme (25 l: 0.0144 units/ml in assay buffer) is added to all wells, except substrate alone controls which receive 25 l assay buffer. (NB: One unit of enzyme activity is defined as the convertase enzyme concentration which converts 1 role substrate/hour).

Plates are incubated for 15 minutes at 26 C. prior to addition of 25 l substrate (40 M stock solution in assay buffer). Plates are then incubated at 26"C for 18 hours and read on aFluoroskan II fluorometer (plates are also read at time 0 to obtain background values). In this test, generally, compounds are of interest if they have activity below 500nM. By way of example the compound of Example 1 gave a figure of 1.5 nM.

Assessment in human cell line (THF-2) The ability of the compounds of this invention to inhibit TNFα production is assessed in TI-IP-1 cells which are a human myelomonocytic cell line which synthesise and secrete TNFa when stimulated with lipopolysaccharide. Tl-IP- 1 cells (4x 105 cells in 160p1 medium RPMI 1640 + bicarbonate, penicillin, streptomycin and glutamine) are incubated with 20p1 of test compounds (triplicates) in DMSO or appropriate vehicle, in a 96 well tissue culture (TC) plate, for 30 min at 37 C in a humidified (5%CO2/95%air) incubator, prior to addition of 20p1 lipopolysaccharide (LPS) (E.STDC0677 Coli. 0111 :B4 (Sigma); final concentration 50 Hg/ml). Each assay includes controls of THP-I cells incubated with medium alone (six wells/plate) or with a standard TNFa inhibitor. 'lhe plates are then incubated for 6 hours at 37 C (humidified incubator) after which time @ 100 l samples are removed from each well and transferred to a 96 well plate for storage at -70 C for subsequent analysis of TNFa concentration by ELISA. In this test, generally, compounds are of interest if they have activity below I OpM.

Assessment in whole blood assay The ability of the compounds of this invention to inhibit TNFa production is also assessed in a human whole blood assay (HWBA). Human whole blood secretes TNFa when stimulated with LPS. This property of blood forms the basis of an assay which is used as a secondary test for compounds which profile as active in the THP- I test.STDC0721 Heparinized (I OUnits/ml) human blood obtained from volunteers is diluted 1:5 with medium (RPM11640 + bicarbonate, penicillin. streptomycin and glutamine) and incubated (160,u1) with 20p1 of test compound (triplicates), in DMSO or appropriate vehicle, for 30 min at 370C in a humidified (5%CO2/95%air) incubator, prior to addition of 20p1 LPS (E. coli. 0111:134; final concentration 1 Optg/ml). Each assay includes controls of diluted blood incubated with medium alone (6 wells/plate) or a known TNFα inhibitor as standard.STDC0404 The plates are then incubated for 6 hours at 370C (humidified incubator), centrifuged (2OOOrpm for 10 min; 4"C), plasma harvested (50-100 l) and stored in 96 well plates at -700C before subsequent analysis for TNFa concentration by ELISA. In this test. generally, compounds are of interest if they have activity below SOuM.

In vivo assessment The ability of the compounds of this invention as ex vivo TNFa inhibitors is assessed in the rat. Briefly, groups of male Wistar Alderley Park (AP) rats (180-21g) are dosed with compound (6 rats) or drug vehicle (10 rats) by the appropriate route e.g. peroral (p.o.), intraperitoneal (i.p.) . subcutaneous (s.c.). Ninety minutes later rats are sacrificed using a rising concentration of C02 and bled out via the posterior vena cavae into 5 Units of sodium heparin/ml blood. Blood samples are immediately placed on ice and centrifuged at 2000 rpm for 10 min at 40C and the harvested plasmas frozen at -200C for subsequent assay of their effect on TNFa production by LPS-stimulated human blood. The rat plasma samples are thawed and 175 l of each sample are added to a set format pattern in a 96U well plate.STDC0606 Fifty l of heparinized human blood is then added to each well, mixed and the plate is incubated for 30 min at 370C (humidified incubator). LPS (25p1; final concentrationlOpg/ml) is added to the wells and incubation continued for a further 5.5 hours. Control wells are incubated with 25 l of medium alone. Plates are then centrifuged for 10 min at 2000 rpm and 200p1 of the supernatants are transferred to a 96 well plate and frozen at -200C for subsequent analysis ofTNF concentration by ELISA.

Data analysis by dedicated software calculates for each compound/dose:Percent inhibition = Mean TNFa (Controls) - Mean TNFa (Treated) X 100 of TNFa Mean TNFa (Controls)Pharmacokinetic test To evaluate the clearance properties of the compounds of this invention a sensitive ex vivo pharmacokinetic test is employed which utilises the CON2 assay to evaluate clearance rate.

This is a generic test which can be used to estimate the clearance rate of compounds across a range of species. Animals (eg. rats, marmosets) are dosed iv with a soluble formulation of compound and at subsequent time points (e.g. 5 10 15 20, 30, 45, 60, 120 min) blood samples are taken from an appropriate vessel into 10U heparin. Plasma fractions are obtained following centrifugation and the plasma proteins precipitated with ethanol (70% final concentration). After 30 mins at 40C the plasma proteins are sedimented by centrifugation and the supernatant fraction is evaporated to dryness using a Savant speed vac.

The sediment is reconstituted in CON2 assay buffer and subsequently analysed for compound content using the TNF convertase assay (CON2). Briefly. a compound concentration- response curve is constructed for the compound undergoing evaluation. Serial dilutions of the reconstituted plasma extracts are assessed for activity and the amount ol' compound present in the original plasma sample is calculated using the concentration-response curve taking into account the total plasma dilution factor.

Test as anti-arthritic agent Activity of a compound as an anti-arthritic is tested as follows. Acid soluble native type II collagen was shown by Trentham et al. to be arthritogenic in rats; it caused polyarthritis when administered in Freunds incomplete adjuvant. This is now known as collagen-induced arthritis (CIA) and similar conditions can be induced in mice and primates.

Recent studies have shown that anti-flNF monoclonal antibodics 121 and TNF receptor-IgG fusion proteins ameliorate established CIA indicating that TNF plays a key role in the pathophysiology of CIA. Moreover, the remarkable efficacy reported for anti-TNF monoclonal antibodies in recent rheumatoid arthritis clinical trials indicates that TNF plays a major role in this chronic inflammatory disease. lhus CIA in DBA/l mice as described in references 2 and 3 is a tertiary model which can be used to demonstrate the anti-arthritic activity of a compound.

1. Trentham, D.E. metal., (1977) J. Exp. Med., 146, 857.

2. Williams, R.O. et al., (1992) Proc Natl Acad Sci, 89, 9784.

3. Williams, R.O. et al., (1995) immunology 84, 433.

In the examples: (a) NMR spectra were taken at 400 MHz; (b) DMF means dimethylformamide; (c) Evaporation of solvents was carried out under reduced pressure; (d) LDA means lithium di-isopropylamide; (e) THF means tetrahydrofuran; (f) DMSO means dimethylsulphoxide; (g) AcOH means acetic acid: (h) DMPU means 1 ,3-dimethyI-3,4.5,6-tetrahydlo-2( 1H)-pyrimidinone; (I) DMAP means dimethylamlnopyridine.

Example 1N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-benzenesulfonylaminosuccinyl]-L-tert-leucine-N1methvlamide EMI23.1 N2-[4-Hydroxy-2R-isobutyl-3S-benzenesulfonylaminosuccinyl]-L-tert-leucine-N1methylamide (600 mg, 1.32 mmol) was dissolved in DMF (10 ml). 1-Hydroxybenzotriazole (231 mg, 1.7 mmol) was added, followed by N-ethyl-N'-(3dimethylaminopropyl)carbodiimide hydrochloride (324 mg, 1.7 mmol) and 2,6-lutidine (181 111, 1.6 mmol). The mixture was stirred at room iemperature for one hour. A solution of hydroxylamine hydrochloride (270 mg, 3.9 mmol) and 2,6-lutidine (453 p1, 3.9 mmol) inDMF (1 ml) was added. The resulting solution was stirred at room temperature for eighteen hours.STDC0862 The resulting mixture was purified by Cl 8 preparative HPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 0/100 to 45/55). Elution yielded the title compound (228 mg; yield: 37%); m.p.= 220-2220C; 'H-NMR (DMSO d-6): 0.77 (d, 3H, J= 5.9 Hz), 0.79 (d. 3H, J= 5.9 Hz). 0.91 (s, 9H), 0.92 (m, 1H), 1.31 (m, 1H), 1.47 (m. 1H), 2.59 (d, 3H, J= 4.4 Hz), 2.73 (m, lH), 3.70 (t br, lH, J= 9.2 Hz), 4.12 (d, lH, J= 9.2 Hz), 7.27 (m, 1H), 7.67-7.52 (m, 4H), 7.75 (d, 211, J= 7.7Hz). 7.89 (m. 1H), 8.82 (s. 1H). 10.74 (s, 111),' MS (ESI): 493 (M + Na+).

N2-[4-Hydroxy-2R-isobutyl-3S-benzenesulfonylammosuccinyl]-L-tert-leucine-N1methylamide used as the starting material was obtained as follows: (i) l o a stirred solution of LDA 175.2 mmol; prepared by addition of 1.6 M n-butyl lithium (47 ml, 75.2 mmol) in hexane to a solution of diisopropylaminc (10.53 ml, 80.3 mmol) in dry THF (120 ml) at -78"C] cooled at -78 C under argon atmosphere was added tert-butyl N(diphenylmethylene)glycinate" @ (22.2 g, 75.2 mmol) in dry THF (170 ml) dropwisc. The mixture was stirred for 15 minutes at -780C and I)MPU (18 ml, 149 mmol) was added dropwise.STDC0594 The mixture was stirred for 30 minutes at -78 C. A solution of benzyl 2Rtrifluoromethanesulfonyloxy-4-methylvalerate(2} (26.3 g, 74.2 mmol) in dry THF (170 ml) was added dropwise to the reaction mixture at -78 C. The mixture was stirred at -780C for one hour and at room temperature for eighteen hours. The solution was diluted in petroleum ether (1000 ml), washed with saturated aqueous ammonium chloride (2 x 600 ml), water (600 ml) and brine (600 ml), dried over MgSO4 and filtered.STDC0807 The solvents were removed and the residue was purified by flash chromatography on silica using petroleum ether-ethyl acetate with 0.5% triethylamine (gradient from 95/5 to 90/10) as eluant to give 1-benzyl-4-tert-butyl-3(R/S)-(N- diphenylmethylene)amino-2R-isobutylbutan-1,4-dioate (36.6 g, R/S 1:3 mixture); 1H-NMR (CDCl3): 0.90-0.81 (m, 6H), 1.39 (s. 9H, 3S isomer), 1.40 (s, 911. 3R isomer), 1.8-1.1 (m, 3H), 3.22 (m, 1H, 3R isomer), 3.38 (m, 1H, 3S isomer). 4.12 (d, 1H, J= 6.6 Hz, 3S isomer), 4.29 (d, 1H, J= 7 Hz, 3R isomer), 5.03 (d, 1H, J= 12.8 Hz, 3R isomer), 5.07 (d, 1H, J= 12.5 Hz, 3S isomer), 5.10 (d, 1H, J= 12.8 Hz, 3R isomer), 5.16 (d, 1H, J= 12.5 Hz, 3S isomer), 7.7-7.1 (m, 5H).

(1) O'Donnell M.J., Polt R.L.; J. Org. Chem, 1982, 47, 2663 (2) F. Hoffmann La Roche AG, (Broadhurst M.J., Brown P.A., Johnston W.I-I., Lawton, G.),Eur. Pat. Appl. EP 497192 A2 ii) A solution of 1 -benzyl-4-tert-butyl-3(R/S)-(N-diphenylmethylene)amino-2R- isobutylbutan-1 4-dioate (20 g, 40 mmol R/S 1:3 mixture) in methanol (250 ml) was hydrogenated in the presence of palladium on charcoal (1.5 g. 10%) under 1 bar pressure for 24 hours. The catalyst was removed by filtration and the solvents were removed in vacuo. The yellow solid was triturated with petroleum ether to give 3(R/S)-amino-2R-isobutylbutan- 1,4- dioic acid 4-tert-butyl ester (8.07 g, 82%.STDC0795 R/S 1:3 mixture) as a white solid; 1H-NMR (DMSO d-6, CD,CO,D): 0.89-0.84 (m. 611). 1.42 (s 9Hs 3S isomer) 1.44 (s, 9H, 3R isomer), 1.7-1.25 (m, 3H). 2.68 (m, 111), 3.63 (s br, 1H, 3S isomer), 3.86 (s br, Ill, 3R isomer) iii) To a slurry of 3(R/S)-ammo-2R-isobutylbutan-1,4-dioic acid 4-tert-butyl ester (6.4 g, 26.1 mmol, R/S 1:3 mixture) in dioxane (40 ml) at 0 C was added IN aqueous sodium hydroxide (58 ml, 58 mmol). The mixture was stirred for five minutes and benzyl chloroformate (5.56 ml, 38.9 mmol) was added dropwise. The mixture was stirred at 0 C for forty five minutes.

The mixture was acidified to pH 1 by addition of 2N hydrochloric acid and extracted with ethyl acetate (2x 100 ml). The organic layers were combined, washed with brine (70 ml), dried over MgSO4. The solvents were evaporated in vacuo to give 3(R/S)benzyloxycarbonylamino-2R-isobutylbutan- 1 ,4-dioic acid 4-tert-butyl ester as a light brown oil which was not purified further. To a solution of 3(R/S)-benzyloxycarbonylamino-2Risobutylbutan-1 ,4-dioic acid 4-tert-butyl ester (from above) in dichloromethane (60 ml) at 0 C was added successively 1 -hydroxybenzotriazole (4.2 g, 31.2 mmol), L-tert-leucine methyl amide (4.4 g, 30.5 mmol), DMAP (4.2 g, 34.4 mmol) and N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (6 g, 31.4 mmol).STDC0302 The mixture was stirred at room temperature for eighteen hours. The solvents were evaporated in vacuo. The residue was partitionned between 2N hydrochloric acid (200 ml) and ethyl acetate (2 x 150 ml). The combined organic layers were washed with saturated sodium bicarbonate, brine, dried overMgSO4.STDC0765 The solvents were evaporated in vacuo and the residue was purified by flash chromatography on silica using ether-petroleum ether (65:35) as eluent to give N2-[2Risobutyl-3 S-benzyloxycarbonylamino-4-tert-butyloxysuccinyll -L-tert-leucine-N' methylamide (8.0 g, 61%) as a white foam; 1H-NMR (CDCl3): 0.90 (d, 611, J= 5.5 Hz), 0.96 (s, 9H). 1.42 (s, 9H), 1.7-1.35 (m, 3H), 2.80(d, IH, J= 4.8 Hz). 2.95 (m, 1H), 4.09 (d, 1H, J= 9.2 Hz), 4.35 (dd, 1H, J= 9.2 Hz, J'=3.3 Hz), 5.13 (s, 211)5.66 (s br, 1H), 6.31 (d br. 1H, J= 6.9 Hz), 7.35-7.25 (m, 5H).STDC0547iv) A solution of N2-[2R-isobutyl-3S-benzyloxycarbonylamino-4-tert-butyloxysuccinyl]-L- tert-leucine-N'-methylamide (3.5 g, 6.9 mmol) in methanol (50 ml) was hydrogenated under 28 PSI pressure for two hours in the presence of palladium on charcoal (700 mg, 10%). The catalyst was removed by filtration and the solvents were removed in vacuo to give N2-l2R- isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (2.57 g, 100%) as a white solid. 1H-NMR (CDCl3):STDC0444 0.91 (d. 3H, 1= 6.6 Hz), 0.96 (d, 3H, J= 6.6 lIz), 1.01 (s, 91 1), 1 white crystals which were collected and dried in vacuo to yield N2-[4-hydroxy-2R-isobutyl- 3S-benzenesulfonylaminosuccinyl]-L-tert-leucine-N1-methylamide (676 mg, 98%)MS (ESI): 456 (M + H+), 478 (M + Na').

Example 2N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(naphthalene-2-sulfonylamino)succinyl]-L-tertlcucine-N1-methylamideEMI27.1 In a manner analogous to that described in the first paragraph of Example 1 except that hydroxylamine hydrochloride and 2,6-lutidine were replaced by O-( tert-butyldimethylsilyl)- hydroxylamine (191 mg, 1.30 mmol), from N2-[4-hydroxy-2R-isobutyl-3S-(naphthalene-2 sulfonylamino)succinyl]-L-tert-leucine-N'-methylamide (480 mg, 0.95 mmol) there was obtained the title compound (362 mg, 73%) as a white solid after addition of 1 ml of 1N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on Ci 8 preparative HPLC using as eluant a mixture of methanol and water/l %AcOH (gradient from 0/100 to 60/40); m.p.= 214-2l60C;STDC0422 111-NMR (DMSO d-6): 0.75 (d. 3H, J= 7Hz), 0.77 (d, 3H, J= 7 Hz), 0.90 (s, 9H), 0.92 (m, 1H), 1.30 (m 1H), 1.46 (m, 1H), 2.60 (d, 3H, J= 4.4 Hz), 2.75 (m, 1H), 3.76 (m, 1H), 4.13 (d, 1H, J= 9.2 Hz), 7.27 (m, 1H), 7.78-7.68 (m, 4H), 7.89 (m, 1H), 8.14-8.06 (m, 3H), 8.39 (s, 1H), 8.79 (s, 1H), 10.79 (s, 1H): MS (ESI): 543 (M + Na*).

The starting material was prepared as follows: In a manner analogous to that described inExample I (v), from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1- methylamide (600 mg, 1.6 mmol) and naphthalene-2-sulfonyl chloride (403 mg), there was obtained N2-12R-isobutyl-3 S-(naphthalene-2-sul fonylamino)-4-tert-butyloxysuccinyl]-L-tert leucine-N1-methylamide (690 mg, 77%) as a white foam: MS (ESI): 584 (M + Na+). This (650 mg, 1.15 mmol), in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl-3 S-(naphthalene-2-sulfonylamino)succinyl]-1 -tert-leucinc-N l methylamide (540 mg, 93%) as a white solid. MS (ESI): 506 (M + H'), 528 (M + Na+).

Example 3N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-acetamidobenzenesulfonylamino)succinyl]-Ltert-leucine-N l -methylamide.EMI28.1 STDC0734In a manner analogous to that described in the first paragraph of Example 1, from N2-l4- hydroxy-2R-isobutyl-3S-(4-acetamidobenzenesulfonylamino)succinyl]-L-tert-leucine-N1methylamide (512 mg, 1 mmol), except that hydroxylamine hydrochloride and 2,6-lutidine were replaced by O-(tert-butyldimethylsilyl)hydroxylamine (191 mg, 1.30 mmol), there was obtained the title compound (335 mg, 63%) as a white solid after addition of 1 ml of IN hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on C18 preparative HPLC using as eluant a mixture of methanol and water/l %AcOH (gradient from 0/100 to 40/60); m.p.= 272-274 C; lH-NMR (DMSO d-6):STDC0451 0.79 (d, 3H, J= 6.2Hz), 0.80 (d, 3H, J= 6.2 Hz), 0.95 (s, 9H), 0.96 (m, 1H), 1.32 (m, 1H), 1.49 (m, 1H), 2.15 (s, 3H), 2.61 (d, 3H, J= 4.4 Hz), 2.72 (m, 1H), 3.67 (m, 1H), 4.16 (d, 1H, J= 9.2 Hz), 7.28 (d, 1H,J= 9.5 Hz), 7.47 (m, 1H), 7.67 (d, 2H, J= 8.8 Hz), 7.73 (d, 2H, J= 8.8 Hz), 7.90 (m, 1H), 8.83 (s, 1H), 10.31 (s, 1H), 10.73 (s, 111); MS (ESI): 550 (M + Na').

The starting material was prepared as follows: In a manner analogous to that described in Example 1 (v), , from N2-[2R-isobutyl-3 S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N ' methylamide (600 mg, 1.6 mmol) and 4-acetamidobenzenesulfonyl chloride (415 mg), there was obtained N2-[2R-isobutyl-3S-(4-acetamidobenzenesulfonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (790 mg, 87%) as a white foam; MS (ESI): 591 (M + Na+). This (750 mg, 1.32 mmol). in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl-3S-(4-acetamidobenzenesulfonylamino)- succinyl]-L-tert-leucine-N1-methylamide (656 mg, 97%) as a white solid: MS (ESI): 513 (M +H+), 535 (M + Na+).

Example 4N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-( naphthalene- 1 -sul fonylamino )succinyll-I -tertIeucine-N'-methvlamide EMI29.1 In a manner analogous to that described in the first paragraph of Example 1, from N2-[4hydroxy-2R-isobutyl-3S-(naphthalene-1-sulfonylamino)succinyl]-L-tert-leucine-N1methylamide (500 mg, 1 mmol), except that hydroxylamine hydrochloride and 2.6-lutidine were replaced by O-(tert-butyldimethylsilyl)hydroxylamine (191 mg, 1.30 mmol), there was obtained the title compound (342 mg, 62%)STDC0754 as a white solid after addition of 1 ml of IN hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on C18 preparative HPLC using as eluant a mixture of methanol and water/1 %AcOH (gradient from 0/100 to 55/45); m.p.= 162-170 C; 'H-NMR (DMSO d-6): 0.65 (d, 3H, J= 5.9Hz), 0.70 (d, 3H, J= 6.2 Hz), 0.91 (m, 1H), 0.92 (s, 9H), 1.20 (m, 1H), 1.35 (m, 1H), 2.60 (d, 3H, J= 4.4 Hz), 2.75 (m, 1H), 3.72 (d br, IH, J= 8.8 Hz), 4.16 (d, 1H, J= 9.2 Hz), 7.45 (m, 1H), 7.80-7.55 (m, 4H), 7.92 (s br, 1H), 8.25-8.05 (m, 3H), 8.67-8.57 (m, 2H), 10.79 (s, 1H);MS (ESI): 543 (M + Na).

The starting material was prepared as follows: In a manner analogous to that described inExample 1 (v), from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1methylamide (600 mg, 1.6 mmol) and naphthalene-l-sulfonyl chloride (403 mg), there was obtained N2-[2R-isobutyl-3S-(naphthalene-1-sulfonylamino-4-tert-butyloxysuccinyl]-L-tertleucine-N'-methylamide (620 mg, 69%) as a white foam; MS (ESI): 584 (M + Na). This (600 mg. 1.06 mmol), in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl-3 S-( naphthalene- 1 -sulfonylamino )succinyl -L-tert- leucine-N'-methylamide (518 mg, 96%) as a white solid. MS (ESI): 506 (M + H+). 528 (M +Na').

Example 5N2-[4-(N-Hydroxyamino )-2R-isobutvl-3 S-(l -methylimidazole-4-sul fonylamino )succinyli-L- tert-leucine-N' -methylamideEMI30.1 In a manner analogous to that described in the first paragraph of Example 1, except that 2.6 equivalents of 1 -hydroxybenzotriazole, 2.6 equivalents of N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride and 2.6 equivalents of 2,6-lutidine were used and hydroxylamine hydrochloride was replaced by O-(tert-butyldimethylsilyl )hydroxylamine (538 mg, 3 eq.), from N2-[4-hydroxy-2R-isobutyl-3S-(1-methylimidazolium-4-sulfonylamino)- succinyl]-L-tert-leucine-N1-methylamide trifluoroacetate salt (700 mg, 1.22 mmol), there was obtained the title compound (265 mg, 46%) as a white solid after addition of water (2 ml)STDC0691 and acetic acid (1 ml) to the crude mixture at the end of the reaction and purification of this mixture on C18 preparative HPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 0/100 to 40/60), 1H-NMR (DMSO d-6): 0.75 (d, 3H, J= 6.2 Hz), 0.76 (d, 3H, J=6.2 Hz), 0.90 (m, 1H), 0.92 (s. 9H), 1.29 (m. 1H), 1.41 (m, 1H), 2.56 (d, 31l, J= 4.4 Hz), 2.75 (m, 1H), 3.62 (t, 1H, J=8.8 Hz), 3.67 (s, 3H), 4.14(d, 1H, J=9.1 Hz), 7.17 (d, 1H. J=9.1 Hz). 7.41 (d, 111, J= 9.2 Hz), 7.51 (s, 111), 7.70 (s, 1H), 7.84 (m, 1H), 8.74 (s, 1H). 10.59 (s.

1H); MS (ESI): 497 (M + Na').

The starting material was prepared as follows: In a manner analogous to that described inExample 1 (v) except that the crude reaction mixture after evaporation of the solvents was directly purified by flash chromatography on silica using dichloromethane-methanol (95:5) as eluant, from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1methylamide (700 mg, 1.88 mmol) and 1-methyl-imidazole-4-sulfonyl chloride (375 mg), there was obtained N2-[2R-isobutyl-3S-(1-methylimidazole-4-sulfonylamino)-4-tert- butyloxysuccinyl]-L-tert-leucine-N1-methylamide (953 mg, 98%) as a white foam.STDC0449 MS (ESI): 516 (M + H+). This (900 mg, 1.74 mmol). in a manner analogous to that described inExample 1 (vi). was converted to N2-[4-hydroxy-2R-isobutyl-3S-(1-methylimidazolium-4- sulfonylamino)succinyl]-L-tert-leucine-Nl-methylamide trifluoroacetate salt (819 mg) as a white solid. MS (ESI): 460 (M-CFlCOOH + H*).

Example 6N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(thiophene-2-sulfonylamino)succinyl]-L-tertleucine-N' -methvlamideEMI31.1 In a manner analogous to that described in the first paragraph of Example I, except that hydroxylamine hydrochloride and 2,6-lutidine were replaced by O-(tert-butyldimethylsilyl)hydroxylamine (191 mg, 1.30 mmol), from N2-[4-hydroxy-2R-isobutyl-3S-(thiophene-2- sulfonylamino)succinyl]-L,-tert-leucine-N'-methylamide (400 mg, 0.86 mmol), there was obtained the title compound (245 mg, 60%)STDC0827 as a white solid after addition of 1 ml of 1N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on C18 preparative HPLC using as cluant a mixture of methanol and water/1%AcOH (gradient from 0/100 to 40/60); lH-NMR (DMSO d-6): 0.75 (d. 3H, J=6.2 l4z), 0.76 (d, 3H,J= 6.2 Hz), 0.91 (s, 9H). 0.93 (m, 1H), 1.29 (m, 1H), 1.46 (m, 1H), 2.56 (d, 3H, J=4.4 Hz), 2.71 (m, 1H), 3.69 (d, 1H, J=9.9 Hz), 4.12 (d, 1H, J=9.1 Hz), 7.10 (t, 1H, J=4.0 Hz), 7.23 (m, 1H), 7.47 (d, 111, J= 4.0 Hz), 7.79 (m. 1H). 7.86 (m. 211), 8.84 (s, 111), 10.75 (s, 1H), MS (ESI): 499 (M + Na').

?'he starting material was prepared as follows: In a manner analogous to that described inExample I (v), from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1- methylamide (500 mg, 1.34 mmol) and thiophene-2-sulfonyl chloride (295 mg), there was obtained N2-[2R-isobutyl 3S-(thophene-2-sulfonylamino-4-tert-butyloxysuccinyl]-L-tertleucine-N1-methylamide (567 mg, 82%) as a white foam;STDC0318 MS (ESI): 540 (M + Na+). This (600 mg, 1.06 mmol), in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy 2R-isobutyl 3S-(thiophene-2-sulfonylamino)succinyl]-L-tert- leucine-N'-methylamide (518 mg, 96%) as a white solid MS (ESI):STDC0876 462 (M + H'), 484 (M + Na+)Example 7N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(3,5-dichlorobenzene-1-sulfonylamino)succinyl]-Ltert-leucine-N1-methylamideEMI32.1 In a manner analogous to that described in the first paragraph of Example 1, except that hydroxylamine hydrochloride and 2.6-lutidine were replaced by O-(tert-butyldimethylsilyl)hydroxylamine (191 mg, 1.30 mmol), from N2-[4-hydroxy-2R-isobutyl-3S-(3,5- dichlorobenzene-1-sulfonylamino)succinyl]-L-tert-leucine-N1-methylamide (450 mg, 0.85 mmol). there was obtained the title compound (310 mg, 68%) as a white solid after addition of 2 ml of 2N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on C1 8 preparative HPLC using as eluant a mixture of methanol and water/ 1%AcOH (gradient from 0/100 to 40/60);STDC0502 'H-NMR (DMSO d-6): 0.75 (d. 3H, J= 6.6 Hz), 0.76 (d, 311, J=6.6 Hz), 0.89 (s, 9H), 0.95 (m, 1H). 1.29 (m. 111). 1.43 (m, 111), 2.56 (d 3H,J= 4.4 Hz), 2.67 (m, 1H), 3.65 (t, 1H, J= 9.5 Hz), 4.12 (d, 1H, J= 9.5 Hz), 7.17 (d, IH, J= 9.5Hz), 7.67 (s, 2H), 7.88 (m 2H)* 8.12 (d, 1H, J=9.5 Hz), 8.86 (s, 1H), 10.79 (s, 1H);STDC0737 MS (ESI): 563 (M{35Cl, 37Cl} + Na'), 561 (M{35Cl, 35Cl} + Na') The starting material was prepared as follows In a manner analogous to that described inExample 1 (v), from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1methylamide (500 mg 1.34 mmol) and 3,5-dichlorobenzenesulfonyl chloride (500 mg), there was obtained N2-[2R-isobutyl-3 S-(3 ,5-dichlorobenzene- 1 -sulfonylamino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (629 mg. 81%) as a white foam. MS (ESI): 604 (M(37C1 35Cl} + Na+). 602 (M{35Cl, 35Cl} + Na+).STDC0244 This (580 mg, 1.0 mmol) in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl- 3S-(3,5-dichlorobenzene-1-sulfonylaminosuccinyl]-L-tert-leucine-N1-methylamide (480 mg.

92%) as a white solid. MS (ESI): 548 (M{37Cl, 35Cl} } + Na), 546 (M(35C1, 35Cl} + Na+) Example 8N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-fluorobenzene-1-sulfonylamino)succinyl]-L-tertleucine-N' -methvlamideEMI33.1 In a manner analogous to that described in the first paragraph of Example 1, except that hydroxylamine hydrochloride was replaced by O-(tert-butyldimethylsilyl)hydroxylamine (186 mg, 1.27 mmol) and 2,6-lutidine (138 l, 1.26 mmol) was added, from N2-[4-hydroxy-2R- isobutyl-3S-(4-fluorobenzenc- 1 -sulfonylamino)succinyl]-L-tert-leucine-N1 -methylamide (400 mg, 0.86 mmol), there was obtained N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-fluoro- benzene-1-sulfonylamino)succinyl]-L-tert-leucine-N1-methylamide (262 mg, 64%)STDC0327 as a white solid after addition of 3 ml of 2N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on C18 preparative HPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 0/100 to 50/50); 'H-NMR (DMSO d-6):STDC0672 0.74 (d, 3H, J=6.2 llz) 0.76 (d, 3H, J=6.2 Hz), 0.89 (s, 9H). 0.90 (m, 1H), 1.29 (m, 1H), 1.44 (m, 1H) 2.57 (d, 3H, J= 4.4 Hz), 2.68 (m, 1H), 3.65 (m, 1H), 4.11 (d, ill. J= 9.2Hz), 7.22 (d, Ill,J= 9.2 Hz), 7.34 (dd, 2H, J=J'=8.8 Hz), 7.65 (m, 1H), 7.76 (dd, 2H, J=8.8 Hz, J'=5.5 Hz), 7.87 (m. 1H). 8.74 (s, 1H), 10.70 (s, 1H), MS (ESI): 511 (M + Na').

The starting material was prepared as follows: In a manner analogous to that described inExample 1 (v), from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1- methylamide (500 mg, 1.34 mmol) and 4-fluorobenzenesulfonyl chloride (393 mg. 2 mmol) there was obtained N2-[2R-isobutyl-3S-(4-fluorobenzene- 1 -sulfonylamino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (522 mg. 74%) as a white foam: MS (ESI): 552 (M + Na+), This (500 mg, 0.94 mmol), in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl-3S-(4-fluorobenzene-1-sulfonylamino)- succinyl]-L-tert-leucine-N1-methylamide (448 mg, 100%) as a white solid. MS (ESI): 474 (M + H+).

Example 9N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(quinoline-8-sulfonylamino)succinyl]-L-tertleucine-N ' -methylamide EMI35.1 In a manner analogous to that described in the first paragraph of Example 1, except that hydroxylamine hydrochloride was replaced by O-(tert-butyldimethylsilyl)hydroxylamine (130 mg 0.88 mmol) and 2,6-lutidine (97 ul, 0.88 mmol) was added, from N2-[4-hydroxy-2R- isobutyl-3S-(quinoline-8-sulfonylamino)succinyl]-L-tert-leucine-N1-methylamide (300 mg, 0.59 mmoi), there was obtained the title compound (190 mg, 59%,)STDC0782 as a white solid after addition of 3 ml of 2N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on Cl 8 preparative HPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 0/100 to 40/60): 111-NMR (DMSO d-6): 0.62 (d, 3H, J= 6.6 Hz), 0.65 (d, 3H, J=6.6 Hz), 0.82 (m, 111), 0.86 (s, 9H), 1.3-1.0 (m, 2H). 2.56 (d, 3H, J= 4.8 Hz), 2.83 (m, III), 3.84 (m. 1H), 4.15 (d, 1H, J= 9.2 Hz), 7.39 (m, 1H), 7.83-7.68 (m, 4H), 8.25-8.19 (m, 2H), 8.53-8.44 (m, 2H), 9.06 (m, 1H), 10.47 (m. 1H); MS (ESI): 522 (M + 544 (M + Na+).

The starting material was prepared as follows: In a manner analogous to that described inExample 1(v), from N2-[2R-isobutyl-3 S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N' methylamide (500 mg, 1.34 mmol) and 8-quinolinesulfonyl chloride (460 mg, 2.02 mmol), there was obtained N2-[2R-isobutyl-3S-(quinoline-8-sulfonylamino)-4-tert-butyloxysuccinyl]- L-tert-leucine-N1-methylamide (375 mg, 50%) as a white foam. MS (ESI): 563 (M + Na+).

This (350 mg, 0.62 mmol), in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl-3S-(quinoline-8-sulfonylamino)succinyl]-L-tertleucine-N'-methylamide (315 mg, 100%) as a white solid. MS (ESI): 507 (M + H+).

Example 10N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-cyanobenzene-1-sulfonylamino)succinyl]-L-tertleucinc-N ' -methylamideEMI36.1 In a manner analogous to that described In the first paragraph of Example 1, except that hydroxylamine hydrochloride, 2,6-lutidine, 1-hydroxybenzotriazole and N-ethyl-N'-(3dimethylaminopropyl)carbodiimide hydrochloride and DMF were replaced by O-(tertbutyldimethylsilyl)hydroxylamine (175 mg, 1.19 mmol). 2-ethoxy-l -ethoxycarbonyl-l ,2- dihydroquinoline (254 mg, 1.03 mmol) and chloroform.STDC0816 from N2-[4-hydroxy-2R-isobutyl-3S (2-cyanobenzene-1-sulfonylamino)succinyl]-L-tert-leucine-N1-methylamide (380 mg, 0.79 mmol), there was obtained the title compound (202 mg, 52%) as a white solid after evaporation of the solvents, partitioning between ether and water, and filtration of the resulting solid. 'H-NMR (DMSO d-6): 0.75 (d, 3H, J= 6.0 Hz), 0.77 (d, 3H, J= 6.0 Hz), 0.91 (m, 1H), 0.93 (s, 911), 1.30 (m, 1H), 1.46 (m, 1H), 2.58 (d, 311, J= 4.4 Hz), 2.84 (m, 111)3.67 (dd, III, J=J'= 9.6 Hz), 4.18 (d, 111, J= 9.2 Hz), 7.56 (d, 1H, J= 9.2 Hz), 8.04-7.76 (m, 611), 8.67 (s, I H), 10.57 (s, 1H); MS (ESI): 518 (M + Na').

The starting material was prepared as follows: In a manner analogous to that described inExample 1 (v), from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1- methylamide (500 mg, 1.34 mmol) and 2-cyanobenzenesulfonyl chloride (407 mg, 2.02 mmol), there was obtained N2-[2R-isobutyl-3 S-(2-cyanobenene- 1 -sulfonylamino)-4-tert- butyloxysuccinyl]-L-tert-leucine-N1-methylamide (507 mg, 71%) as a white foam; MS (ESI): 559 (M + Na+). This (480 mg) in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl-3S-(2-cyanobenzene-1-sulfonylamino)succinyl]-Ltert-leucine-N1-methylamide (400 mg, 93%) as a white solid. MS (ESI): 481 (M + H'), 503 (M+Na').

Example 11N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(3-pyridinesulfonylamino)succinyl]-L-tert-leucineN -methvlamide EMI37.1 In a manner analogous to that described in the first paragraph of Example 1 except that hydroxylamine hydrochloride was replaced by O-(tert-butyldimethylsilyl)hydroxylamine (205 mg) and 2,6-lutidine (153 p1) was used, from N2-[4-hydroxy-2R-isobutyl-3S-(3-pyridine- sulfonylamino)succinyl]-L-tert-leucine-N1-methylamide (320 mg, 0.7 mmol), there was obtained the title compound (315 mg, 94%)STDC0850 as a white solid after addition of 2 ml of 2N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on Cl 8 preparative HPLC using as eluant a mixture of methanol and water/l %AcOH (gradient from 0/100 to 35/65); m.p.= 228-231 0C; 'H-NMR (DMSO d-6): 0.75 (d, 311, J= 6.6Hz), 0.76 (d, 3H, J= 6.6 Hz), 0.88 (s, 9H). 0.90 (m, 1H), 1.29 (m, 1H), 1.44 (m, 1H), 2.56 (d, 3H, J=4.8 Hz), 2.68 (m, 1H), 3.69 (d br. 1H, J=9.9 Hz), 4.10 (d, 1H, J=9.5 Hz), 7.20 (m, 1H), 7.56 (dd, 1H, J=4.8 Hz, J'=8 Hz), 7.87 (m, 1H), 7.96 (m, 1H), 8.04 (d, 1H, J=8 Hz), 8.76 (d, 1H, J=4.8 Hz), 8.81 (m, 1H), 8.86 (s, 1H), 10.75 (m, 1H); MS (ESI):STDC0042 494 (M +Na).

The starting material was prepared as follows: In a manner analogous to that described inExample 1 (v), from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N methylamide (500 mg, 1.34 mmol) and 3-pyridinesulfonyl chloride (360 mg), there was obtained N2-[2R-isobutyl-3S-(3-pyridinesulfonylamino)-4-tert-butyloxysuccinyl]-L-tertleucine-N1-methylamide (500 mg, 73%) as a white foam; MS (ESI): 513 (M + H+), 535 (M + Na+). This (470 mg, 0.92 mmol), in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl-3S-(3-pyridinesulfonylamino)succinyl]-L-tert- leucine-N1-methylamide (340 mg) as a white solid; MS (ESI): 457 (M + H+), 479 (M + Na+).

Example 12N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6sulfonylamino)succinyl]-L-tert-leucine-N1-methylamideEMI38.1 In a manner analogous to that described in the firsi paragraph of Example 1. except that hydroxylamine hydrochloride was replaced by O-(tert-butyldimethylsily)hydroxylamine (273 mg) and 2,6-lutidine (202 p1) was used, from N2-[4-hydroxy-2R-isobutyl-3S-(1-methyl-2-oxo- 1,2,3 ,4-tetrahydroquinoline-6-sulfonylamino)s '-methylamide (500 mg, 0.92 mmol).STDC0484 there was obtained N3-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(1 -methyl-2- oxo-1,2,3,4-tetrahydroquinoline-6-sulfonylamino)succinyl]-L-tert-leucine-N1-methylamide (322 mg, 63%) as a white solid after addition of 2 ml of 4N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on Ci 8 preparative HPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 0/100 to 50/50).

m.p.= 260-2620C; 1iI-NMR (DMSO d-6): 0.74 (d, 3H, J= 6.6 Hz), 0.76 (d, 31-1, J= 6.6 Hz), 0.90 (m, 1H), 0.91 (s, 9H), 1.28 (m, 1H), 1.44 (m, 1H), 2.56 (d, 3H, J= 4.4 Hz), 2.59 (m, 2H), 2.69 (m, 1H), 2.92 (m, 2H), 3.29 (s, 3H), 3.63 (m, 1H), 4.12 (d, 1H, J=9.1 Hz), 7.17 (d, 1H, J= 8.4Hz), 7.25 (d, 1H, J= 8.8 Hz), 7.42 (m, 1H), 7.57 (m, 2H), 7.85 (m, 1H), 8.76 (s, 1H), 10.72 (s, 1H); MS (ESI): 576 (M t Na').

The starting material was prepared as follows: In a manner analogous to that described inExample 1(v) , from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1- methylamide (500 mg, 1.34 mmol) and 1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonyl chloride(note) (524 mg), there was obtained N2-[2R-isobutyl-3S-(1-methyl-2-oxo-1,2,3,4tetrahydroquinoline-6-sulfonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (679 mg, 85%) as a white foam; MS (ESI): 617 (M + Na'). This (650 mg, 1.09 mmol) in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2Risobutyl-3S-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonylamino)succinyl]-L-tert leucine-N'-methylamide (520 mg. 88%) as a white solid. MS (ESI): 539 (M + H-). 561 (M + Na').

(floe) Imperial Chemical Industries PLC, ICI-Pharma S.A.; (Bruneau, P.); Eur. Pat. Appl. EP 462812 A2Example 13N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(5-dimethylaminonaphthalene-1sulfonylamino )succinyl 1-L-tert-leucine-N' -methylamideEMI39.1 In a manner analogous to that described in the first paragraph of Example 1, except that no 1 hydroxybenzotriazole was added and that hydroxylamine hydrochloride and 2,6-lutidine were replaced by O-(tert-butyldimethylsilyl)hydroxylamine (262 mg), from N2-[4-hydroxy-2R- isobutyl-3S-(5-dimethylaminonaphthalene-1-sulfonylamino)succinyl]-L-tert-leucine-N1methylamide (490 mg, 0.89 mmol), there was obtained the title compound (270 mg, 54%) as a solid after addition of 2 ml of acetic acid, methanol (20 ml) and water (10 ml)STDC0845 to the crude mixture at the end of the reaction, stirring overnight and purification of this mixture on C18 preparative HPLC using as eluant a mixture of methanol and water/l % AcOH (gradient from 0/100 to 60/40). m.p.= 170-174 C; 1H-NMR (DMSO d-6): 0.62 (d, 3H, J= 6.2 Hz), 0.66 (d, 3H, J= 6.2 Hz), 0.87 (s, 9H), 0.90 (m, 1H), 1.17 (m, 111), 1.32 (m, 111), 2.56 (d, 3H, J= 4.8Hz), 2.74 (m, 1H), 2.84 (s, 6H), 3.69 (m, 1H), 4.13 (d, 1H, J= 8.8 Hz), 7.25 (d, 1H, J= 7.7 Hz), 7.44 (m, 1H), 7.57 (m, 2H), 7.77 (m, 1H), 7.88 (m, 1H), 8.07 (d, 1H, J= 7 Hz), 8.19 (d, 1H, J= 8.4 Hz), 8.43 (d, 1H, J= 8.4 Hz), 8.66 (s, 1H), 10.6 (s, 1H); MS (ESI): 586 (M + Na4).

The starting material was prepared as follows: In a manner analogous to that described inExample I (v) except that after completion of the reaction the mixture was diluted with ethyl acetate, washed with 5% sodium bicarbonate and purified by flash chromatography on silica gel, from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (500 mg, 1.34 mmol) and dansyl chloride (473 mg). there was obtained N2-[2R-isobutyl-3S- (5-dimethylaminonaphthalene- 1 -sulfonylamino )-4-tcn-butyloxysuccinylj-L-tert-leucine-N1 - methylamide (660 ing, 81%) as a foam.STDC0853 MS (ESI): 627 (M + Na'). 'ihis (630 mg, 1.04 mmol), in a manner analogous to that described in Example 1 (vi), was convcrted to N2-[4-hydroxy2R-isobutyl-3 S-(5-dimethylaminonaphthalene- 1 -sulfonylamino )succinyl i-L-tert-leucine-N methylamide (518 mg, 91%) as a solid MS (ESI) 549 (M + H+),Example 14N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-tert-butylbenzene-1-sulfonylamino)succinyl]-Ltert-leucine-N' -methylamideEMI40.1 In a manner analogous to that described in the first paragraph of Example 1, except that no 1hydroxybenzotriazole was added and that hydroxylamine hydrochloride and 2,6-lutidine were replaced by O-(tert-butyldimethylsilyl)hydroxylamine (167 mg), from N2-[4-hydroxy-2Risobutyl-3S(4-tert-butylbenzene-1-sulfonylamino)STDC0468succinyl]-L-tert-leucine-N1-methylamide (387 mg, 0.75 mmol), there was obtained the title compound (272 mg, 70%) as a white solid after addition of 2 ml of 4N hydr Hz), 2.73 (m, 1H), 3.69 (m, 1H), 4.10 (d, 1H, J=9.1 Hz), 7.27 (d, 1H, J=8.8 Hz), 7.48 (d, 1H, J= 9.1 Hz), 7.54 (d, 2H, J= 8.4 Hz), 7.66 (d, 2H, J= 8.4 Hz), 7.87 (m, 1H), 8.85 (s. 1H), 10.71 (s, 1H); MS (ESI): 549 (M + Na').

The starting material was prepared as follows: In a manner analogous to that described inExample 1(v), from N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1- methylamide (500 mg. 1.34 mmol) and 4-tert-butylbenzene sulfonyl chloride (410 mg), there was obtained N2-[2K-isobutyl-3 S-(4-tert-butylbenzene- 1 -sul fonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (660 mg) as a white foam. MS (ESI): 590 (M + Na+).

This (63() mg), in a manner analogous to that described in Example 1 (vi). was converted to N9-14-hydroxy-2R-isobutyl-3 S-(4-tert-butylbenzene- 1 -sulfonylamino )succinyl]-L-tert-leucine- Nl-methylamide (407 mg) as a white solid; MS (ESI): 512 (M + H+).

Example 15N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(oxindole-5-sulfonylamino)succinyl]-L-tert-leucineN'-methvlamideEMI41.1 In a manner analogous to that described in the first paragraph of Example 1, except that no 1 hydroxybenzotriazole was added and that hydroxylamine hydrochloride and 2,6-lutidine were replaced by O-(tert-butyldimethylsilyl)hydroxylamine (203 mg), from N2-[4-hydroxy-2Risobutyl-3S-(oxindole-5-sulfonylamino)succinyl]-L-tert-leucine-N1 -methylamide (470 mg, 0.92 mmol), there was obtained the title compound (228 mg, 47%) as a white solid after addition of 2 ml of 4N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on Cl 8 preparative HPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 0/100 to 45/55).STDC0718 m.p.= 232-234 C; 1H-NMR (DMSO d-6): 0.73 (d, 3H, J=6.6 Hz). 0.74 (d, 3H, J=6.6 Hz), 0.85 (m, 1H), 0.90 (s, 911), 1.27 (m, 1H, 1.41 (m, 1H), 2.56 (d, 311, J= 4.8 Hz). 2.68 (m, 1H), 3.53 (s, 2H), 3.59 (m, 1H), 4.11 (d, 1H, J= 9.1 Hz), 6.86 (d 111, J= 8 Hz), 7.25 (m, 1H), 7.32 (m, 1H), 7.52 (s 111)7.55 (d, 1H, J=8 Hz) 7.85 (m, 1H), 8.76 (s, 1H), 10.69 (s, 1H), 10.75 (s, 1H): MS (ESI): 548 (M + Na+).

The starting material was prepared as follows.' (i) In a manner analogous to that described in example 1(v) from N2-[2R-isobutyl-3S-amino- 4-tert-butyloxysuccinyll-L-tert-leucine-Nl-methylamide (500 mg. 1.34 mmol) and oxindole-5sulfonyl chloride (Note) (405 mg), there was obtained N2-[2R-isobutyl-3S-(oxindole-5- sulfonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (660 mg) as a white foam. MS (ESI): 589 (M + Na+). This (630 mg). in a manner analogous to that described inExample l (vi). was converted to N2-[4-hydroxy-2R-isobutyl-3S-(oxindole-5-sulfonylamino)- succinyl]-L-tert-leucine-N1-methylamide (496 mg) as a solid.STDC0120 MS (ESI): 533 (M + Na+), (Note) Prepared by reaction of oxindole with chiorosulfonic acid.

Example 16N2-[4-(N-Hydroxyamino) 2R-isobutyl 3S-(quinoline 6-sulfonylamino)succinyl]-L-tert-leucineN' -methylamideEMI42.1 In a manner analogous to that described in the first paragraph of Example 1, except that no 1hydroxybenzotriazole was added and that hydroxylamine hydrochloride and 2,6-lutidine were replaced by O-(tert-butyldimethylsi lyl)hydroxylamine (352 mg), from N2-[4-hydroxy-2R- isobutyl-3S-(quinoline-6-sulfonylamino)succinyl]-L-tert-leucine-N1 -methylamide (500 mg) there was obtained the title compound (204 mg) as a white solid after addition of 2 ml of 2N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on C18 preparative HPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 0/100 to 50/50). m.p.= 248-250 C;STDC0753 1H-NMR (DMSO d-6): 0.72 (d 311, J= 7Hz). 0.74 (d, 3H, J= 7 Hz), 0.85 (s, 9H). 0.89 (m, 1H), 1.27 (m. 1H), 1.45 (m, 1H), 2.56 (d, 311, J=4.4 Hz), 2.70 (m 1H), 3.73 (m, 1H), 4.11 (d, 1H, J= 9.1 Hz), 7.22 (d. 1H, J= 9.1 Hz), 7.68 (m, 1H), 7.83 (m, 211), 7.97 (d, 1H, J= 9.1 Hz), 8.12 (d, 1H, J= 9.1 Hz). 8.43 (s, 1H). 8.54 (d, 1M, J= 9.1 lIz), 8.74 (s, 1H), 9.05 (m, 1H), 10.76 (s, 1H); MS (ESI): 522 (M + H').

The starting material was prepared as follows: In a manner analogous to that described inExample 1(v) except that the reaction mixture was directly purified by flash chromatography on silica gel after evaporation of the solvents, from N2-[2R-isobutyl-3S-amino-4-tert-butyloxy- succinyl]-L-tert-leucine-N1-methylamide (500 mg, 1.34 mmol) and quinoline-6-sulfonyl chloride(Note) (400 mg), there was obtained N2-[2R-isobutyl-3S-(quinoline 6-sulfonylamino)-4tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (510 mg, 67%) as a white foam. MS (ESI): 563 (M + H'). This (490 mg), in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl-3S-(quinoline-6-sulfonyl-amino)succinyl]-L-tert-leucine-N1-methylamide (530 mg) as a white solid.STDC0315 MS (ESI): 507 (M + H+), (Note) Quinoline 6-sulfonyl chloride was prepared in two steps: preparation of quinoline-6sulfonic acid from sulfanilic acid (Ponci R, Gialdi, F; Chem. Abstracts, 1955, 49,1 1657b) followed by reaction of quinoline-6-sulfonic acid with phosphorus pentachloride.

Example 17N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(isoquinoline-5-sulfonylamino)succinyl]-L-tertleucine-N1-methylamide EMI44.1 In a manner analogous to that described in the first paragraph of Example 1, except that no I hydroxybenzotriazole was added and that hydroxylamine hydrochloride and 2,6-lutidine were replaced by O-(tert-butyldimethylsilyl)hydroxylamine (250 mg), from N2-[4-hydroxy-2R isobutyl-3S-(isoquinoline-5-sulfonylamino)succinyl]-L-tert-leucine-N1-methylamide (430 mg), there was obtained the title compound (204 mg)STDC0396 as a white solid after addition of 2 ml of 2N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on C18 preparative HPLC using as eluant a mixture of methanol and water/l%AcOH (gradient from 0/100 to 40/60). m.p.= 208-210 C; 'H-NMR (DMSO d-6):STDC0673 0.67 (d, 3H, J= 6.6Hz), 0.71 (d, 3H, J= 6.6 Hz), 0.89 (s, 911)0.90 (m, 1H), 1.23 (m, 1H), 1.41 (m, 1H), 2.56 (d, 3H, J= 4.4 Hz), 2.70 (m, 1H), 3.69 (m, 1H), 4.14 (d, 1H, J= 9.1 FIz). 7.35 (d, 1H, J= 9.1 Hz), 7.76 (t, 1H, J= 7.7 Hz), 7.90 (m, 1H), 7.99 (d, 1H, J= 8.8 Hz), 8.27 (d, 1H, J= 7.7 Hz), 8.33 (d, 1H, J= 6.3 Hz), 8.39 (d, 1H, J= 7.7 Hz), 8.57 (s, 1H), 8.71 (d, 1H, J= 6.3 Hz), 9.45 (s, 1H), 10.60 (s. 1H); MS (ESI): 522 (M + H+),The starting material was prepared as follows:STDC0820 In a manner analogous to that described inExample 1 (v) except that the reaction mixture was directly purified by flash chromatography on silica gel after evaporation of the solvents, from N2-[2R-isobutyl-3S-amino-4-tert-butyloxy- succinyl]-L-tert-leucine-N1-methylamide (500 mg, 1.34 mmol) and isoquinoline-5-sulfonyl chloride (500 mg), there was obtained N2-[2R-isobutyl-3S-(isoquinoline-5-sulfonylamino)-4tert-butyloxysuccinyl]-L-tert-leucine-N'-methylamide (580 mg, 77%) as a white foam. MS (ESI): 585 (M + Na+). This (550 mg), in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl-3 S-(isoquinoline-5-sulfonylamino)- succinyl]-L-tert-leucine-N1-methylamide (450 mg) as a white solid; MS (ESI): 507 (M + H+).

Example 18N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(1,2,3,4-tetrahydroquinoline-8sulfonylamino )succinyll-L-tert-leucinc-N @ -methylamideEMI45.1 A solution of N2-[4-(N-hydroxyamino)-2R-isobuty 1-3 S-(quinoline-8-sulfonylamino)succinyl]- L-tert-leucine-NI-methylamide (250 mg, 0.48 mmol) in methanol (20 ml) was stirred under an atmosphere of hydrogen (50 PSI) in the presence of 10% palladium on charcoal (100 mg) for 5 hours. The solids were filtered off and the solvents were evaporated in vacuo. The residue was purified by Cl 8 preparative HPLC using as eluant a mixture of methanol and water/l %AcOH (gradient from 0/100 to 45/55).STDC0695 Evaporation of the solvents and trituration of the residue with ether yielded the title compound (211 mg; yield: 84%); 1H-NMR (DMSO d-6): 0.74 (m, 6H), 0.78 (m, 1H), 0.90 (s, 9H). 1.25 (m, 1H), 1.39 (m. 1H), 1.81 (m, 2H), 2.56 (d. 3H, J= 4.4 Hz), 2.69 (m, 3H), 3.30 (m, 2H). 3.59 (m, 1H), 4.13 (d, 111, J= 9.2 Hz), 5.96 (s, 1H), 6.47 (t, 1H, J= 7.7 Hz), 7.04 (d, 1H, J= 7 Hz), 7.32 (d, 1H, J= 7 Hz), 7.40 (m, 2H), 7.85 (m, 1H), 8.70 (s, 1H), 10.50 (s, 1H); MS (ESI): 548 (M + Na+).

Example 19N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(quinoline-8-sulfonylamino)succinyl]-L-tertleucine-N1-(dimethylamino)ethylamide EMI46.1 In a manner analogous to that described in the first paragraph of Example 1, except that that hydroxylamine hydrochloride and 2,6 lutidine were replaced by O-(tert-butyldimethylsilyl)- hydroxylamine (101 mg).STDC0671 from N2-[4-hydroxy-2R-isobutyl-3S-(quinoline-8-sulfonylamino)- succinyl]-L-tert-leucine-N1-(dimethylammomum)ethylamide trifluoroacetate (298 mg, 0.53 mmol), there was obtained the title compound (50 mg. 16%) as a white solid after addition of 1 ml of 1N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on Cl 8 preparative HPLC using as eluant a mixture of methanol and water/ 1%AcOH (gradient from 0/100 to 40/60); 'H-NMR (DMSO d-6): 0.63 (m, 6H), 0.86 (s, 9H).

0.90 (m, 1H), 1.3-1.0 (m, 2H), 2.49 (s, 6H), 2.60 (m, 2H), 2.80 (m, 1H), 3.20 (m, 2H), 3.80 (m, 1H), 4.10 (d, 1H, J= 9.2 Hz), 7.30 (m, 1H), 7.68 (m, 2H), 7.80 (m, 1H), 8.0 (m, 1H), 8.16 (m, 1H, J= 9.5 Hz), 8.22 (d, 1H, J= 9.5 Hz), 8.50 (m, 2H), 9.04 (m, 1H), 10.47 (m, 1H); MS (ESI): 579 (M + H+) The starting material was prepared as follows: (i) To a solution of 3(R/S)-amino-2R-isobutylbutan- 1,4-dioic acid-4 tert-butyl ester (1 g, 4.1 mmol) in acetonitrile (32 ml) was successively added quinoline-8-sulfonyl chloride (1.2 g, 5.3 mmol) and triethylamine (1.4 ml). The mixture was heated at 40-45 C for 20 minutes and cooled to room temperature. The solvents were evaporated in vacuo.STDC0412 The residue was dissolved in ethyl acetate and acidified with hydrochloric acid. The organic layer was dried over MgSO4. After evaporation of the solvents, the residue was purified by C 18 preparativeHPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 45/55 to 70/30) to yield 3R-(quinoline-8-sulfonylamino)-2R-isobutylbutan-1 ,4-dioic acid-4-tcrt-butyl ester.STDC0727 Further elution yielded 3S-(quinoline-8-sulfonylamino)-2R-isobutylbutan-1 ,4-dioic acid-4-tert-butyl ester (942 mg). 'H-NMR (CDCI3): 0.89 (d, 3H. J= 6.2 Hz), 0.91 (d, 3H, J= 6.2 Hz), 0.94 (s. 9H), 1.8-1.4 (m, 3H), 3.06 (m. 1H), 4.40 (s br, 1H), 7.59 (m, 2H). 8.03 (d, 111 J= 8.4 Hz), 8.25 (d, 1H, J= 8.4 Hz), 8.37 (d, 111, J= 7.3 Mz), 9.09 (m 1H) (ii) To a solution of 3S-(quinoline-8-sulfonylamino)-2R-isobutylbutan- 1 ,4-dioic acid-4-tertbutyl ester (225 mg.STDC0494 0.52 mmol) in DMF (1.5 ml) at 0 C was added successively 1hydroxybenzotriazole (84 mg, 0.62 mmol), L-tert-leucine dimethylaminoethylamide"N"""" (114 mg, 0.57 mmol), DMAP (63 mg. 0.52 mmol). and N-ethyl-N'-(3-dimethylaminopropyl)- carbodiimide hydrochloride (118 mg, 0.62 mmol). The mixture was stirred at room temperature for eighteen hours. The solvents were evaporated in vacuo. The residue was partitioned between water and ethyl acetate.STDC0523 The organic layer was washed with saturated sodium bicarbonate brine and dried over MgSO4. The solvents were evaporated in vacuo and the residue was purified by flash chromatography on silica using acetone-dichloromethane (gradient from 0:100 to 50:50) as eluant to give N2-[2R-isobutyl-3S-(quinoline-8- sulfonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-(dimethylamino)ethylamide (218 mg 61%) as a white foam. MS (ESI): 620 (M + H).

(iii) In a manner analogous to that described in Example 1 (vi), from N2-[2R-isobutyl-3S- (quinoline-8-sulfonyl)amino-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-(dimethylamino)ethylamide (220 mg. 0.40 mmol), there was obtained N2-[4-hydroxy-2R-isobutyl-3S(quinoline-8-sulfonylamino)succ nyll-L-tert-leucine-N l -(dimethylammonium)ethylamide trifluoroacetate (194 mg, 91%) as a solid; MS (ESI): 564 (M + H+), (Note) L-tert-leucine dimethylaminoethylamide was prepared by the reaction of L-tert-leucine with triphosgene to give 3-(S)-tert-butyloxazolidine-1,4-dione which was then treated withN,N-dimethylethylenediamine.

Example 20N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(quinoline-8-sulfonylamino)succinyl]-L-tertleucine-N' -morphojinoethylamide EMI48.1 In a manner analogous to that described in the first paragraph of Example 1 except that hydroxylamine hydrochloride and 2,6 lutidine were replaced by O-(tert-butyldimethylsilyl)- hydroxylamine (102 mg), from N2-l4-hydroxy-2R-isobutyl-3S-(quinoline-8-sulfonylamino)succinyl]-L-tert-leucine-N1-morpholinoethylamide (210 mg, 0.347 mmol), there was obtained the title compound as a white solid after addition of 1 ml of IN hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on C1 8 preparative HPLC using as eluant a mixture of methanol and 0.2% aqueous ammonium carbonate (gradient from 0/100 to 40/60);STDC0487 1j-NMR (DMSO d-6 + TFA d-l): 0.66 (m, 6H), 0.86 (s, 9H), 0.90 (m, 1H), 1.25 (m. H) 2.90 (m. 1H), 3.15 (m, 4H), 3.43 (m, 4H), 3.67 (m, 2F1), 3.82 (d, 1H, J= 8.8 Hz), 4.0 (m, 3H), 7.70 (m, 2H), 8.20 (m. 1H), 8.25 (d, 1H, J= 7.8 Hz), 8.51 (d, 1H, J= 8.3 Hz), 9.04 (m, 1H); MS (ESI): 621 (M + H+).

The starting material was prepared as follows: (i) To a solution of 3S-(quinoline-8-sulfonylamino)-2R-isobutylbutan- 1 ,4-dioic acid-4-tertbutyl ester (370 mg, 0.85 mmol) in DMF (2.5 ml) at 0 C was added successively 1hydroxybenzotriazole (137 mg, 1.02 mmol), L-tert-leucine morpholinoethylamide(N 'e) (227 mg, 0.93 mmol), DMAP (103 mg, 0.85 mmol) and N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (194 mg, 1.02 mmol). The mixture was stirred at room temperature for eighteen hours. The solvents were evaporated in vacuo. The residue was partitioned between water and ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, brine, dried over MgSO4.STDC0377 The solvents were evaporated in vacuo and the residue was purified by flash chromatography on silica using acetone-dichloromethane (gradient from 50:50 to 100:0) as eluant to give N2-[2R-isobutyl-3S-(quinoline-8- sulfonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-morpholinoethylamide (400 mg, 71%) as a white foam. MS (ESI): 662 (M + H').

(ii) In a manner analogous to that described in Example 1 (vi), from N2-[2K-isobutyl-3S (quinoline-8-sulfonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N morpholinoethylamide(400 mg, 0.60 mmol), there was obtained N2-[4-hydroxy-2R-isobutyl3S-(quinoline-8-sulfonylamino)succinyll-L-tert-lcucine-N'-morpholinoethylamide (159 mg) as a solid after evaporation of the solvent and purification of this mixture on C1 8 preparativeHPLC using as eluant a mixture of methanol and 0.2% aqueous ammonium carbonate (gradient from 40/60 to 50/50). MS (ESI): 606 (M + H').

(Note) I,-tert-leucine morpholinoethylamide was prepared by the reaction of l,-tert-leucine with triphosgene to give 3-(S)-tert-butyloxazolidine- 1.4-dione which was then treated with morpholinoethylamine.

Example 21N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-oxo-3,4-dihydroquinazoline-8sulfonylamino)succinyl i-L-tert-leucine-N1 -methelamide EMI49.1 In a manner analogous to that described in the first paragraph of Example 1, except that no 1hydroxybenzotriazole was added and that hydroxylamine hydrochloride and 2,6-lutidine were replaced by O-(tert-butyldimethylsi lyl)hydroxylamine (135 mg), from N2-[4-hydroxy-2R- isobutyl-3S-(4-oxo-3,4-dihydroquinazoline-8-sulfonylamino)succinyl]-L-tert-leucine-N1methylamide (240 mg, 0.46 mmol), there was obtained the title compound (158 mg, 64%)STDC0773 as a solid after addition of 2 ml of 2N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on C 1 8 preparative HPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 0/100 to 45/55); 'Il-NMR (I)MSO d-6): 0.71 (m, 6H), 0.89 (s, 9H), 0.90 (m, 1H), 1.25 (m, 111). 1.35 (m, ill), 2.56 (d, 3H, J= 4.4Hz), 3 76 (m, 1H), 4.17 (d, 1H, J=9.2 Hz), 7.14 (d, 1H, J=9.9 Hz), 7.59 (t, 1H, J=7.9 Hz), 7.76 (d, 1H, J= 9.5 Hz), 7.84 (m, 111), 8.16 (d, ill, J= 7.9 Hz). 8.24 (s, 1H), 8.31 (d, 1H, J= 7.9 lIz), 8.48 (s, 1H), 10.44 (s, 1H); MS (ESI): 539 (M + H').

The starting material was prepared as follows.' (i) In a manner analogous to that described in Example 1(v), from N2-{2R-isobutyl-3S-amino- 4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (750 mg. 1.34 mmol) and a mixture (Note) of 4-oxo-3,4-dihydroquinazoline-6-sulfonyl chloride and 4-oxo-3,4-dihydroquinazoline-8sulfonyl chloride (1.5 g, 1:1), there was obtained N2-[2R-isobutyl-3S-(4-oxo-3,4- dihydroquinazoline-8-sulfonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (332 mg) as a foam (MS (ESI):STDC0317 602 (M t Na@)) and N2-[2R-isobutyl-3S-(4-oxo-3,4 dihydroquinazoline-6-sulfonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-methylamide (428 mg) after purification on HPI,C using ethyl acetate as eluant (MS (ESI): 602 (M + Na')).

(ii) In a manner analogous to that described in Example 1 (vi), from N2-[2R-isobutyl-3S-(4- oxo-3,4-dihydroquinazoline-8-sulfonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1methylamide (300 mg, 0.51 mmol), there was obtained N2-[4-hydroxy-2R-isobutyl-3S-(4-oxo3,4-dihydroquinazoline-8-sulfonylamino)succinyl]-L-tert-leucine-N1-methylamide (260 mg) as a solid. MS (ESI): 524 (M + H').

(Note) Prepared by reaction of 3,4-dihydroquinazolin-4-one with chlorosulfonic acidExample 22N2-[4-(N-hydroxyamino)-2R-isobutyl-3S-(4-oxo-3,4-dihydroquinazoline-6sulfonylamino)succinyl]-L-tert-leucine-N1-methylamide EMI51.1 In a manner analogous to that described in the first paragraph of Example 1, except that no 1hydroxybenzotriazole was addcd and that hydroxylamine hydrochloridc and 2,6-lutidine were replaced by O-(tert-butyldimethylsily)hydroxylamine (191 mg), from N2-[4-hydroxy-2Risobutyl-3S-(4-oxo-3,4-dihydroquinazoline-6-sulfonylamino)succinyl]-L-tert-leucine-N1methylamide (340 mg 0.65 mmol). there was obtained the title compound (195 mg.STDC0805 56%) as a solid after addition of 2 ml of 2N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on Cl 8 preparative HPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 0/100 to 45/55); 'H-NMR (DMSO d-6): 0.73 (m, 611), 0.88 (s, 9H), 0.90 (m, 1H), 1.27 (m, 1H), 1.43 (m, 1H), 2.56 (d, 111, J= 4.4 Hz), 2.67 (m, 1H), 3.67 (m, 1H), 4.11 (d, 1H, J= 9.2 Hz), 7.21 (d, 1H, J= 9.5Hz), 7.75 (d. 111, J= 8.5 Hz), 7.85 (m 2H), 8.02 (dd, 1H, J= 8.5 Hz, J'= 2.2 Hz), 8.24 (s, 1H), 8.44 (s, 11I), 10.74 (s, 1H);MS (ESI): 539 (M + H+).

The starting material was prepared as follows: (i) In a manner analogous to that described in Example I (vi), from N2-[2R-isobutyl-3S-(4- oxo-3 ,4-dihydroquinazoline-6-sulfonylamino)-4-tert-butyloxysucciny 1] -L-tert-leucine-N ' methylamide (400 mg, 0.69 mmol), [see Example 21] there was obtained N2-[4-hydroxy-2Risobutyl-3S-(4-oxo-3,4-dihydroquinazoline-6-sulfonylamino)succinyl]-L-tert-leucine-N1methylamide (360 mg) as a solid. MS (ESI): 524 (M + H').

Example 23N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(quinoline-8-sulphonylamino)succinyl]-L-tertleucine-N1-(dimethylamino)propylamide EMI52.1 In a manner analogous to that described in the first paragraph of Example 1, except that hydroxylamine hydrochloride was replaced by O-(tert-butyldimethylsilyl)hydroxylamine (102 mg), from N2-[4-hydroxy-2R-isobutyl-3S-(quinoline-8-sulphonylamino)succinyl]-L-tertleucine-N1-(dimethylammonium)propylamide trifluoroacetate (200 mg 0.32 mmol), there was obtained the title compound (60 mg, 29%) as a white solid after addition of 1 ml of IN hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on Cl 8 preparative HPLC using as eluant a mixture of methanol and water/l %AcOH (gradient from 10/90 to 40/60). 1H-NMR (D,O):STDC0558 0.7 (d, 3H, J = 6.6 Hz), 0.72 (d, 3H, J = 6.6Hz), 1.02 (m, 1H), 1.06 (s, 9H), 1.2-1.36 (m, 211), 1.95 (m, 2H), 2.86 (m, 1H), 2.88 (s, 6H), 3.15 (m, 2H), 3.31 (m, 2H), 3.81 (d, 111, J = 9.5 Hz), 4.2 (s, 1H), 7.74 (m, 111). 7.8 (m, 1H), 8.32 (d, 1H, J= 8.0 Hz), 8.38 (dd, 1H, J= 7.3 Hz, J = 1.5 Hz), 8.53 (dd, 1H, J= 8.4 Hz, J = 1.5Hz), 9.07 (dd, 1H, J= 4.4 Hz, J = 1.5 Hz); MS (ESI) : 593 (M + H').

The starting material was prepared as follows:In a manner analogous to that described in Example 19 ii), from 3S-(quinolin-8yl)sulphonylamino-2R-isobutylbutan-1,4-dioic acid 4-tert-butyl ester (330 mg, 0.75 mmol) and L-tert-leucine dimethylaminopropylamide(Note) (179 mg, 0.83 mmol) there was obtainedN2-[2R-isobutyl-3S-(quinoline-8-sulphonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1 (dimethylamino)propylamide (258 mg, 54%) as a white solid: MS (ESI): 634 (M + H').

This (250 mg, 0.4 mmol), in a manner analogous to that described in Example 1 (vi), was converted to N2-[4-hydroxy-2R-isobutyl-3S-(quinoline-8-sulfonylamino)succinyl]-L-tert- leucine-N1-(dimethylammonium)propylamide trifluoroacetate (220 mg, 97%) as a white powder. MS (ESI): 578 (M + H+).

(Notc) L-tert-ieucinc dimethylaminopropylamide was prepared by the reaction of L-tert-leucine with triphosgene to give 3-(S)-tert-butyloxazolidine-1,4-dione which was then trcated with N,N-dimethylpropylenediamine Example 24 N2-[4-(N-Hydroxyamino)-2R-isobutyl-3S-(quinoline-8-sulphonylamino)succinyl]-L-tertleucine-N -dimethylamide EMI53.1 In a manner analogous to that described in the first paragraph of Example 1, except that that hydroxylamine hydrochloride was replaced by O-(tert-butyldimethylsilyl)hydroxylamine (94 mg), from N2-[4-hydroxy-2R-isobutyl-3S-(quinoline-8-sulphonylamino)succinyl]-L-tertleucine-N'-dimethylamide (280 mg, 0.54 mmol), there was obtained the title compound (140 mg, 49%)STDC0317 as a white solid after addition of 0.5 ml of 1N hydrochloric acid to the crude mixture at the end of the reaction and purification of this mixture on C1 8 preparative HPLC using as eluant a mixture of methanol and water/1%AcOH (gradient from 20/80 to 50/50). 11l-NMR (D2O):STDC0693 0.66 (d, 3H, J = 6.2 Hz), 0.68 (d, 3H, J = 6.2Hz), 1.04 (s, 9H), 1.07 (m, 1H), 1.1-1.28 (m, 2H), 2.83 (m, 1H), 2.94 (s, 3H), 3.22 (s. 3H), 3.84 (d, 1H, J = 9.2 Hz), 4.91 (d, 1H, J = 9.2Hz), 7.75-7.8 (m, 2H), 8.18 (d, 111, J = 8.8Hz), 8.31 (d, 1H, J= 8.2 Hz), 8.38 (dd, 1H, J= 7.3Hz, J = 1.5 Hz), 8.51 (dd, 1H, J= 8.4 Hz, J = 1.5Hz), 9.07 (dd, 1H, J= 4.4 Hz, J = 1.5 Hz); MS (ESI) : 536 (M + H') and 558 (M + Na').

The starting material was prepared as follows:In a manner analogous to that described in Example 19 (ii), from 3S-(quinoline-8-sulphonyl- amino)-2R-isobutylbutan-1,4-dioic acid 4-tert-butyl ester (295 mg, 0.67 mmol) and L-tertleucine dimethylamide(Note) (118 mg, 0.74 mmol) there was obtained N2-[2R-isobutyl-3S- (quinoline-8-sulphonylamino)-4-tert-butyloxysuccinyl]-L-tert-leucine-N1-dimethylamide (339 mg, 87%) as a white solid. MS (ESI): 577 (M + II') and 599 (M + Na').

This, in a manner analogous to that described in Example 1 (vi), was converted to N2-[4- hydroxy-2R-isobutyl-3S-(quinoline-8-sulfonylamino)succinyl]-L-tert-leucine-N1dimethylamide (280 mg, 97%) as a white powder; MS (ESI): 521 (M + H'). STDCDBPG0242* (Note) L-tert-leucine dimethylamide was prepared by the reaction of L-tert-leucine with triphosgene to give 3-(S)-tert-butyloxazolidine-1,4-dione which was then treated with a saturated solution of dimethylamine.

Example 25A number of compounds were prepared by solid phase synthesis according to the following general procedure.

A gas dispersion tube (with N2-12R-isobutyl-3 S-amino-4-(N -oxyamino)succinyl]-L- tert-leucine-N '-methylamide linked via the oxygen atom of the N-oxyamino group to SASRIN resin (100 mg, ca 0.05 mmol) inside) was placed in a test tube and 25% pyridine in diebloromethane (3 ml, v/v) was added, followed by a sulfonyl chloride (0.3 mmol) in dichloromethane (1 ml). The mixture was agitated in a sonicated bath for 2 hours. The gas dispersion tube was drained and sparged with nitrogen. The standard protocol for washing the resin consisted in adding dichloromethane (2x6 ml), methanol (2x6 ml) and dichloromethane (2x6 ml) into the gas dispersion tube, followed by agitation by sonication for 5 minutes, and finally draining by gravity and sparging with nitrogen.STDC0156 To the resin in a gas dispersion tube (itself placed in a test tube) was added 5% trifluoroacetic acid in dichloromethane (5 ml). The mixture was agitat

N2- [2R-Isobutyl-3 S-amino 4-(N-oxyamino)succinyl -tert-leucine-N-methylamide loaded onSASRIN resin was prepared as follows: (i) To a solution of 3(R/S)-amino-2R-isobutylbutan-1,4-dioic acid-4-tert-butyl ester (4.7 g, 19. 1 mmol, R/S 1:3 mixture) in a mixture of dioxane (50 ml) and 10% aqueous sodium carbonate (100 ml) cooled at 0 C was added a solution of 9-fluorenylmethyl chloroformate (5 g, 19.3 mmol) in dioxane (80 ml) dropwise. The mixture was warmed to room temperature and stirred for onc hour. The mixture was acidified to pH 3 by addition of 4N hydrochloric acid, extracted with ethyl acetate.STDC0802 The organic layer was washed with brine. dried over MgSO4, and the solvents were evaporated in vacuo to give 3(R/S)-(9-fluorenylmethoxycarbonylamino)-2R- isobutylbutan-l,4-dioic acid-4-tert-butyl ester as a white solid (ii) To a solution of crude 3(R/S)-(9-fluorenylmethoxycarbonylamino)-2R-isobutylbutan- 1,4- dioic acid-4-tert-butyl ester in dichloromethane (70 ml) was added L-tert-leucine methylamide (3.8 g) and N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (4.4 g 23.0 mmol). The mixture was stirred for 3 hours, diluted with ethyl acetate. washed with 1N hydrochloric acid and brine. The organic layer was dried over MgSO4.STDC0279 The residue was purified by chromatography on silica gel using dichloromethane/acetonitrile (85:15) as eluant to give N2-[2R-isobutyl-3S-(9-fluorenylmethoxycarbonylamino)-4-tert-butyloxysuccinyl]-L tert-leucine-N-methylamide (4.0 g) as a white foam.

'H-NMR (CDCl3): 0.93 (d, 6H, J= 6.3 Hz). 1.00 (s, 9H), 1.44 (s, 9H), 1.7-1.4 (m, 3H) 2.82 (d, 3H, J= 4.8 Hz), 2.99 (m, 1H), 4.14 (d, 1H, J= 9.2 Hz), 4.50-4.20 (m, 411), 5.70 (m, 111), 6.40 (m, 2H), 7.30 (m, 211), 7.39 (m, 2H), 7.63 (m, 2H), 7.76 (m, 2H).

(iii) To a solution of N2-[2R-isobutyl-3 S-(9-fluorenylmethoxycarbonylamino)-4-tert- butyloxysuccinyl]-L-tert-leucine-N -methylamide (4 g, 6.74 mmol) in dichloromethane (20 ml) was added trifluoroacetic acid (20 ml). The mixture was stirred for 18 hours at 0 C. The solvents were evaporated in vacuo. The residue was taken up in toluene and the solvent was removed in vacuo (three times). The residue was triturated in a mixture of pentanelether (1:1) to give white crystais which were collected and dried in vacuo to yield N2-[2R-isobutyl-3S-(9fluorenylmethoxycarbonylamino)-4-hydroxysuccinyl] -L-tert-leucine-N1 -methylamide (3.6 g).

1H-NMR (DMSO d-6): 0.83 (m. 15H) 1.10 (m, 111), 1.37 (m, 1H). 1.52 (m, 1H), 2.56 (d, 3H,J= 4.4 Hz), 2.97 (m, 1H), 3.97 (m, 1H), 4.35-4.10 (m. 411), 7.90-7.10 (m. 1111) (iv) 4-(Hydroxymethyl)-2-methoxyphenoxymethyl-copoly(styrenc 1 %divinyl benzene )-resin (SASRIN resin)(Note) (2.6 g ca 0.7 mmol/g loading, 1.8 mmol) was suspended in dry chloroform (100 ml) and gently agitated for 30 minutes under a blanket of argon. Nhydroxyphthalimide (2.71 g, 16.6 mmol) and triphenylphosphine (4.36 g, 16.6 mmol) were added. The mixture was stirred for 15 minutes. Diethylazodicarboxylate (2.6 ml, 1 6.6 mmol) was added dropwise and the mixture was shaken for 72 hours.STDC0190 The resin was collected by filtration, washed successively with chloroform (3x100 ml) methanol (3x100 ml), dichloromethane 3x100 ml). ether (3x100 ml) and dried.

'3C NMR (gel in CDCI): 55.4, 69.7, 74.2, 99.1, 163.4; IR: 1730 (Note) Prepared from chloromethyl-copoly(styrene-1%divinylbenzene)-resin (Merrifield resin, supplied by Bachem, loading: 0.8-1 mmol/g) according to Mergler M, Tanner R, Gosteli J, Grogg P, Tetrahedron Lett., 1988. 29, 4005 (v) The resin described in (iv) (3.6 g. ca 0.6 mmol/g) was suspended in methanol (100 ml) for 30 mn. To this mixture was added hydrazine hydrate (0.77 ml, 15.8 mmol). The mixture was stirred at room temperature for 18 hours.STDC0678 The resin was collected by filtration, washed successively with methanol (3xl00 ml), dichloromethane (3x100 ml), ethyl acetate (3x100 ml) ether (3x100 ml) and dried to give 4-(aminoxymethyl)-2-methoxyphenoxymethylcopoly(styrene- 1 %divinylbenzene)-resin. (Estimation of the loading was assessed by dosing the liberated phthalhydrazide: 0.5-0.7 mmol/g) 13C NMR (gel in THF d-8): 58.1, 73.0, 75.4, 102.2 (vi) 4-(Aminoxymethyl)-2-methoxyphenoxymethyl-copoly(styrene- 1 %divinylbenzene)-resin (7.5 g, ca 0.5 mmol/g loading, 3.75 mmol) was suspended in DMF (200 ml) and gently agitated for 30 minutes.STDC0482 To this slurry was successively added N2-[2R-isobutyl-3S-(9- fluorenylmethoxycarbonylamino)-4-hydroxysuccinyl]-L-tert-leucine-N1-methylamide (2.62 g, 4.88 mmol) N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (3.6 g, 18.8 mmol) and DMAP (600 mg). The mixture was shaken for 72 hours and the resin was collected by filtration, washed successively with DMF (2x100 ml), dichloromethane (100 ml), methanol (2x100 ml), dichloromethane (100 ml), ether (100 ml) and dried.

(FMOC group deprotection)The resin was shaken with a solution of 25% piperidine in DMF (v/v, 200 ml) for 4 hours The resin was collected by filtration, washed with DMF (2x100 ml), methanol (2x100 ml), dichloromethane (2x 100 ml), ether (100 ml) and dried to give 8.65 g of SASRIN resin grafted with N2-[2R-isobutyl-3 S-amino 4-(N-oxyamino)succinyl]-L-tert-leucine-N -methylamide.

Compounds of the formula prepared by the general procedure of Example 25: EMI57.1 Compound a b c dEMI57.2 MS(M+I-I+) Retention time (mins) 513 9.8 617 8.6 513 7.5 539 9.0 e f g h kEMI58.1 515 6.6 511 8.6 549 8.8 555 9.3 561 9.5 549 7.0 523 8.0 505 8.5 m n oP q r s uEMI59.1 513 9.8 539 9.2 516 7.9 501 7.3 597 12.6 513 515 554 8.2 490 7.2 Yields were in the range 11-23 mg.

Example 26Typical tablet formulations for a compound of this invention or a pharmaceutical ly-acceptable salt thereof ('Compound X') are: (a) Tablet Formulation 1 mg/tablet Compound X... 100 Lactose Ph.Eur.... 179 Croscarmellose sodium.... 12 Polyvinylpyrrolidone.... 6 Magnesium stearate.... 3 (b) Table Formulation II mg/tablet Compound X 250 Lactose Ph.Eur 215 Croscarmellose sodium 20 Polyvinylpyrrolidone 10 Magnesium stearate 5The tablets may be prepared by conventional procedures well known in the pharmaceutical art and may be film coated with typical coating materials such as hydroxypropylmethylcellulose.